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ABSTRACT 
 
The majority of breast cancer deaths occur due to metastasis, with the most 
common site of distant breast cancer metastasis being bone. Previous work in our 
laboratory has established that stem-like breast cancer cells with high aldehyde 
dehydrogenase (ALDH) activity and expression of a CD44+CD24- phenotype have 
enhanced metastatic capacity. This study tested the hypothesis that bone-derived 
osteopontin (OPN) promotes the migration and stem-like behavior of breast cancer cells. 
We demonstrate that bone-derived OPN promotes migration, tumorsphere-forming 
ability and colony-forming ability of whole population and ALDHhiCD44+CD24- breast 
cancer cells in bone marrow-conditioned media (an ex vivo representation of the bone 
microenvironment). We observed that cell surface receptors CD44 and RGD-dependent 
integrins facilitate these behaviors via OPN, potentially through activation of WNK-1, 
PRAS40 and HSP60 signaling in breast cancer cells. Our analysis of the interactions 
between bone-derived OPN and breast cancer cells provides valuable insight regarding 
breast cancer cell metastasis to bone.   
 
Keywords: Breast cancer, Metastasis, Bone microenvironment, Osteopontin, Cancer 
stem cell, CD44, Integrins 
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1 INTRODUCTION 
 
Cancer is responsible for 1 in 7 deaths worldwide; it causes more deaths than 
AIDS, malaria and tuberculosis combined [1]. According to the International Agency for 
Research on Cancer, there were approximately 14 million new cancer cases in 2012 - by 
2030, this number is expected to surge to 21.7 million new cases [1]. This projected 
increase in cancer prevalence is due to the expanding and aging global population and the 
adoption of lifestyles known to increase cancer risk, including poor diet, physical 
inactivity and exposure to carcinogens [1]. 
Breast cancer is an example of a type of malignancy that is and will remain a 
major global health challenge [1, 2]. It is currently the most frequently diagnosed cancer 
amongst women and is the second leading cause of cancer-related deaths in North 
America. It is estimated that breast cancer cases will also increase in the coming years 
due to less frequent and delayed pregnancies in women, as well as reduced breast-feeding 
[1, 2].  Even though we have seen a drastic improvement in the treatment of breast cancer 
patients over the last 25 years, there remains a deplorable gap in our ability to manage 
metastatic breast cancer patients. In order to significantly reduce the impact of breast 
cancer on women worldwide, it is imperative that we focus on researching the biology, 
prevention and treatment of metastatic disease.  
This thesis focuses on investigating the potential mechanisms of breast cancer 
metastasis to bone, since bone is the most common site of distant metastases in breast 
cancer patients [3, 4]. Specifically, it aims at elucidating the role of the soluble bone-
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derived factor osteopontin (OPN) and its interactions with breast cancer cells that may 
contribute to the establishment of bone tumor burden in breast cancer patients.   
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2 LITERATURE REVIEW 
 
2.1 Cancer 
Cancer is a group of diseases characterized by dynamic changes in the genome 
that cause normal cells to evolve progressively to highly malignant derivatives. The 
multistep nature of tumorigenesis includes the acquisition of sustained proliferative 
signaling, replicative immortality, the evasion of growth suppressors and cell death, 
induced angiogenesis and the ability to invade and metastasize to other tissues [5]. These 
neoplastic characteristics are further amplified by tumor-promoting inflammation and the 
deregulation of cellular energetics, as well as the tumor cell’s ability to evade the immune 
response and recruit ostensibly healthy cells to contribute to the progression of the 
disease [6].   
Cancer is currently a major health challenge worldwide and in Canada [7]. 
Approximately 2 in 5 Canadians are expected to develop cancer in their lifetime and a 
quarter of Canadians will die from their disease [7]. Cancer is responsible for 30% of all 
deaths in Canada, making it the leading cause of death and premature death (measured in 
potential years of life lost) in the country [7]. In addition to the social ramifications this 
disease entails, cancer has major economic consequences for our country [7]. In 2000, it 
was the fourth most costly disease in Canada, amounting to $17.4 billion in physician and 
hospital expenditure and loss of productivity due to premature death [7]. The social and 
economic toll that cancer has on Canadians is expected to increase as the aging 
population continues to grow.  
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2.2 Breast Cancer 
Breast cancer is the most frequently diagnosed cancer among Canadian women, 
accounting for 26.1% of all newly diagnosed cancer cases in 2015 [2]. Discovering and 
implementing effective treatments for this disease is dependent on elucidating the 
underlying mechanisms in its formation and progression. Research advances in the past 
half century have shown that breast cancer is a genetically and clinically heterogeneous 
disease, arising from the malignant transformation of epithelial cells lining the milk ducts 
or the milk-producing lobules in the breast [8]. It can be broadly classified into in situ 
carcinoma and invasive (infiltrating) carcinoma; further sub-classifications are 
determined based on the cell type of origin, histological representation and molecular 
phenotypes [9]. Breast cancers classified as in situ (still confined within the duct or 
lobule of origin) have an excellent prognosis if treated appropriately; when caught at this 
stage, patients with ductal carcinoma in situ (DCIS) have a 99.2% overall 5-year survival 
rate [10].  
Breast cancer patients diagnosed with invasive carcinoma do not fare as well, 
since their disease has invaded the surrounding breast tissue and has possibly spread to 
lymph nodes and other organs. Molecular classification of breast cancers has proven to be 
particularly useful in stratifying patients based on relative risk of recurrence and 
progression; these classifications are based on estrogen and progesterone receptor status, 
human epidermal growth receptor 2 (HER2/neu) status, and proliferative index as 
measured by Ki67 [9, 11]. One major benefit of these molecular classifications is their 
use in the determination of which patients are likely to respond to targeted therapies (e.g. 
tamoxifen or aromatase inhibitors for ER+/PR+ patients and trastuzumab, pertuzumab or 
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lapatinib for HER2/neu patients) [11]. Despite these recent advances in targeted therapy, 
breast cancer still ranks second in mortality amongst all other cancers, since patients with 
metastatic breast cancer have a mere 22% chance of surviving longer than ten years. This 
is primarily due to the failure of conventional therapy to mitigate and eliminate metastatic 
disease [2, 7].  
2.3 Metastasis 
Understanding the underlying molecular mechanisms of the metastatic process is 
vital to the development of novel therapeutics that can effectively treat metastatic cancer. 
Past research has helped elucidate the multistep nature of cancer metastasis. Tumor cells 
first escape the primary tumor and intravasate into the circulatory or lymphatic system. 
The blood and lymphatic systems are used as transportation routes to the secondary site, 
where cancer cells can exit the vasculature into the tissue site, at which point they can 
grow into micrometastases and subsequently to clinically detectable macrometastases 
[12]. The metastatic process is surprisingly inefficient; Luzzi et al  (1998) determined that 
only 0.02% of a melanoma cell population formed macrometastases in the mouse liver 
after being injected intraportally. It is the ability to initiate growth after extravasation and 
to continue to grow into clinically detectable macrometastases that proves most difficult 
for cancer cells during the metastatic cascade [13]. 
2.4 Cancer Stem Cells 
The cancer cells that do successfully complete the metastatic process are not 
random. It has been shown that breast cancer tumors exhibit distinct molecular subtypes 
(luminal A, luminal B, basal-like, HER2-overexpressing, normal breast-like, and claudin-
6 
 
low) and consist of a hierarchy of phenotypically and functionally different cells [9, 14]. 
A subpopulation of aggressive cells is believed to exist at the apex of this hierarchy, and 
these cells have the propensity to initiate the primary tumour and successfully metastasize 
to adjacent tissues and distant organs [14-17]. These cells have been termed “cancer stem 
cells” (CSCs) because of their unique ability to self-renew and differentiate into a 
heterogeneous tumor, contrasting with their non-CSC counterparts that are incapable of 
tumor propagation [14, 15, 18-20]. Although the cell-of-origin of the CSC has not yet 
been definitively identified, CSCs are hypothesized to arise via one of three different 
mechanisms: a normal stem cell may acquire tumorigenic properties through aberrant 
mutations; a more differentiated progenitor may dedifferentiate into a stem-like state; or 
mature differentiated cancer cells acquire mutations that result in de-differentiation and 
co-opting of primitive stem cell signaling pathways, thus forming a CSC. Recent work by 
multiple groups support the progenitor hypothesis, as it has been shown that 
subpopulations within breast cancer cells can interconvert between stem-like, basal or 
luminal phenotypes and CSCs and non-CSCs can be generated after oncogenic 
reprogramming of differentiated fibroblasts [21, 22].  
Stem-like breast cancer cells can be isolated by selecting for specific cell surface 
markers. Using cells isolated from pleural effusions or primary tumors of breast cancer 
patients, Al-Hajj et al (2003) identified and isolated tumor-initiating cells by 
fluorescence-activated cell sorting based on a CD44+CD24-/low phenotype [23]. As few as 
100 cells of this phenotype were able to form tumors in immune-compromised mice 
while tens of thousands of cells with alternate phenotypes failed to form tumors [23]. 
They also showed that CD44+CD24-/low cells could be serially passaged; these cells where 
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able to recapitulate the heterogeneous nature of the original tumor, containing 
CD44+CD24-/low cells in addition to a myriad of other cellular phenotypes present within 
the primary tumor [23]. Sheridan et al (2006) later showed that breast  cancer cell lines 
containing >30% of CD44+CD24- cells (MDA-MB-231, MDA-MB-436, Hs578T, 
SUM1315, and HBL-100) express higher levels of pro-invasive genes, including IL-1α, 
IL-6, IL-8, and urokinase plasminogen activator (UPA) and have highly invasive 
properties [24].  
The value of CD44 as a CSC marker is of little surprise considering that it is 
capable of promoting multiple tumorigenic properties. CD44 participates in a variety of 
signaling networks, including the activation of Rho GTPases (integral in cytoskeletal 
remodeling and invasion) and the PI3K/Akt and MAPK-Ras pathways (promotion of 
growth, survival and invasion) [25]. CD44 facilitates cell migration by serving as a 
docking site for matrix metalloproteases (MMPs) and matrix-modifying enzymes that 
degrade components of the extracellular matrix, such as collagen [25].  
Ginestier et al (2007) added an additional component to the breast CSC phenotype 
by demonstrating that cells with high aldehyde dehydrogenase activity (ALDHhi) isolated 
from healthy human breast tissue have phenotypic and functional characteristics of 
mammary stem cells and that ALDHhi human breast carcinoma cells contain a CSC 
subpopulation [26]. This study also showed that ALDHhi cells are capable of generating 
tumors when as little as 500 cells are implanted into the mammary fat pad of NOD/SCID 
mice. Investigation of the relative hierarchy of the ALDHhi and CD44+CD24- phenotypes 
demonstrated that the combined phenotype of ALDHhiCD44+CD24- resulted in the 
greatest tumor-initiating capacity, while cells displaying an ALDHloCD44+CD24- 
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phenotype were not tumorigenic even when implanting 50,000 cells/fat pad [26], 
suggesting that ALDH activity is essential for identifying the tumor-initiating 
subpopulation in breast cancer cells (Figure 1).  
Prior to the elucidation of ALDH’s function as a biomarker for cancer stem cells, 
ALDH was known to play a self-protective role in normal stem cells. The ALDH enzyme 
superfamily catalyzes the oxidation of endogenous and exogenous aldehydes into their 
corresponding carboxylic acids and thus protects organisms from potentially harmful 
aldehydes [27]. ALDH also offers cellular protection against cytotoxic drugs in both 
normal mammary stem cells and CSCs; Tanei et al (2009) showed that ALDH+ tumor 
cells and ALDH expression significantly increased in breast cancer patients following 
neoadjuvant chemotherapy consisting of paclitaxel and epirubicin and that ALDHhigh 
breast tumors are correlated with resistance to neoadjuvant chemotherapy [28]. ALDH 
also plays a role in the expansion and differentiation of normal and cancer stem cells; 
when ALDH activity is inhibited, hematopoietic and cancer stem cells shift into a more 
differentiated state [29-31]. This shift in CSCs increases their sensitivity to chemotherapy 
and renders them less aggressive [31-33].  
The Allan lab has recently pioneered functional characterization of 
ALDHhiCD44+CD24- breast cancer cells in relation to metastatic behavior. Croker et al  
(2012) demonstrated for the first time that ALDHhiCD44+CD24- stem-like breast cancer 
cells have enhanced capacity for cell growth, colony formation, migration, invasion 
through Matrigel and adhesion to select extracellular matrix components in vitro. Croker 
et al (2012) also used in vivo studies employing standard experimental metastasis assays, 
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Figure 1. Stem-like ALDHhiCD44+CD24- Breast Cancer Cells 
The primary breast tumor is made up of cancer cells with multiple different cell 
phenotypes. Stem-like breast cancer cells can be isolated by their high aldehyde 
dehydrogenase activity and CD44+/CD24- phenotype (ALDHhiCD44+CD24-); these cells 
have the ability to self-renew and differentiate into a secondary tumor [16, 34].  
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which involved injection into the tail vein, or spontaneous metastasis assays involving 
orthotopic injection into the mammary fat pad and showed that the ALDHhiCD44+CD24- 
phenotype selects for breast cancer cells with enhanced tumorigenic and metastatic 
capacity relative to non stem-like ALDHlowCD44-CD24+ breast cancer cells [34]. 
2.5 Metastatic Organ Tropism 
In addition to the findings that only a subset of aggressive cancer cells can 
successfully metastasize, clinical observations demonstrate that metastatic cells have a 
specific affinity for certain tissues and organs, a quality referred to as organ tropism [35, 
36]. Breast cancer, for example, commonly metastasizes to the lymph nodes, lung, liver, 
bone and brain [37]. It was first proposed in 1889 by Stephen Paget that certain tissues 
are predisposed to developing secondary metastases. Paget’s ‘seed and soil’ hypothesis 
states that metastatic dissemination depends on crosstalk between a subset of cancer cells 
(the ‘seeds’) and specific organ microenvironments (the ‘soil’) [37]. A cancer cell’s 
altered genetic or molecular signature and unique cell surface receptors result in a 
predilection for certain microenvironments, and in turn a favorable niche will provide 
conditions to promote tumor growth [38].  
2.6 Breast Cancer Metastasis to Bone 
Of particular interest is breast cancer’s preference for bone, as this is the most 
common site of metastasis in breast cancer patients. Coleman and Rubens (1987) found 
that the incidence of bone metastases was significantly higher (69%) than lung (27%) and 
liver (27%) metastases and that bone was the most common site for first distant relapse 
[39]. These observations are not unique to breast cancer, as bone is also a common site of 
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metastasis in myeloma, prostate, thyroid, bladder and lung cancer [40]. Bone metastases 
pose significant challenges for a patient’s quality of life and treatment of their disease as 
skeletal metastases are associated with significant morbidity and poor prognosis; breast 
cancer patients that develop bone metastases survive approximately 22 months post-
diagnosis. Breast cancer bone lesions are generally osteolytic in nature; bone homeostasis 
is disrupted by the upregulation of osteoclast activity, bone resorption dominates and 
there is little new bone formation [40]. These physiological changes compromise skeletal 
integrity and result in bone pain, pathological fractures, spinal cord compression and 
reduced patient mobility [39, 40]. Hypercalcaemia (serum calcium > 3.0 mmol/L) is also 
a significant metabolic complication in patients and if left untreated, can result in 
dysfunction of the gastrointestinal tract, renal failure and central nervous system 
complications such as cardiac arrhythmias [40].  
Breast cancer mainly forms bone metastases in the metaphyseal bone of the axial 
skeleton (ex. vertebrae, ribs, sternum) and the ends of long bones [40, 41]. The 
metaphysis is largely composed of metabolically active trabecular bone and is surrounded 
by hematopoietic marrow, fatty marrow and blood vessels [42, 43]. In agreement with 
Paget’s seed and soil hypothesis, bone metastases of all cancer types occur almost 
exclusively in active red marrow, an attractive site for metastatic involvement because of 
its characteristic sinusoidal vascular spaces and relatively easy barrier for tumor cell 
penetration [3, 40]. Physical properties of the circulation within the bone marrow cavity, 
such as capillary structure and slow blood flow, likely also contribute to this observed 
pattern of metastases [40].  
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In conjunction with the physical properties and blood flow patterns characteristic 
of metaphyseal bone, bone marrow offers circulating tumor cells an optimal pre-
metastatic niche via a wide variety of chemokines, such as stromal cell-derived factor-1 
(SDF-1), C-X-C motif chemokine 10 (CXCL10) and other proteins, including 
osteopontin (OPN) and angiopoietin [44, 45]. Once breast cancer cells arrest in the bone, 
they influence the activity of osteoclasts and osteoblasts in such a way that results in 
constitutive osteoclast activation and a down-regulation of osteoblast production of bone 
matrix, causing sustained bone degradation [3, 46]. In healthy bone, osteoblasts 
externally express receptor/activator for NF-κB ligand (RANKL), which binds to RANK 
on the surface of monocytes to promote fusion of several of these cells into a 
multinucleated osteoclast [42]. Activated osteoclasts adhere to the bone matrix through 
αvβ3, αvβ5 and α2β1 cell surface integrins and secrete acidic and lysosomal enzymes that 
cause bone resorption and increased bone turnover [42]. Breast cancer cells have the 
ability to hijack this mechanism by secreting a variety of cytokines, chemokines and 
other factors including parathyroid hormone-related peptide (PTHrP), interleukin 1 (IL-
1), IL-6, IL-8, IL-11, cyclooxegenase 2 (COX-2) and prostaglandin E2 that have all been 
shown to stimulate osteoclastogenesis by up-regulating RANKL expression [3, 46]. 
These secreted factors can influence osteoclast physiology in a RANKL independent 
manner by binding directly to receptors on the surface of osteoclasts; for example, IL-8 
can bind directly to CXCR1 to effect osteoclast differentiation and activity [47].  
During breast cancer cell-induced bone resorption, growth factors usually locked 
in the bone matrix such as transforming growth factor β (TGF-β), insulin-like growth 
factor (IGF) 1 and 2, fibroblast growth factor (FGF) 1 and 2, platelet-derived growth 
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factor (PDGF), and bone-morphogenetic proteins (BMPs) are released into the bone 
microenvironment, creating a niche in which cancer cells can grow [44, 45, 48, 49]. 
These growth factors also stimulate the secretion of metastasis-promoting factors from 
breast cancer cells such as connective tissue growth factor (CTGF), IL-11 and PTHrP, 
thereby creating a vicious cycle of bone resorption and tumor growth [50, 51] (Figure 2). 
The bone metastatic niche is also influenced by bone marrow stromal cells and transient 
cells (erythrocytes, T-cells and platelets) [3, 46]. Mesenchymal stem cells in the bone 
marrow give rise to stromal cells that can differentiate into osteoblasts, chondrocytes, 
adipocytes or fibroblasts. These stromal cells are known to support the proliferation, 
migration, and survival of breast cancer cells, specifically through vascular cell adhesion 
molecule-1 (VCAM-1). When VCAM-1 is blocked via a neutralizing antibody, bone 
osteolysis decreases [52]. Additionally, adipocytes are known to secrete IL-6, tumor-
necrosis factor-α (TNF-α) and leptin, all responsible for stimulating bone resorption and 
inhibiting osteoblast proliferation [53, 54], while fibroblasts can secrete inactive MMP-2 
that is activated by breast cancer cells to increase invasiveness and migration [55]. 
Platelets and T-cells may also assist in the establishment of metastases by expressing 
RANKL secreting factors such as lysophosphatidic-acid (LPA) and tumour necrosis 
factor α (TNF-α) to further increase osteoclast activity [56, 57]. Interestingly, as bone 
resorption is up-regulated, TGF-β is released and functions to suppress the activity of T-
cells; this suppresses the immune response and may allow breast cancer cells to escape 
immune surveillance [58]. Notably, the bone marrow represents a rich supportive niche 
for hematopoietic stem cells [59] and it has been shown that most early-disseminated 
breast cancer cells in bone have a stem-like phenotype, observations that complement the  
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Figure 2. Breast cancer cells and the bone microenvironment interact in a vicious 
cycle. 
The bone microenvironment contains multiple cell types, including osteoblasts, 
osteoclasts and stromal cells that secrete a myriad of growth factors and cytokines to 
offer a niche conducive to the establishment and progression of breast cancer metastases. 
Once breast cancer cells arrest in bone, they cause bone degradation via the upregulation 
of osteoclastic activity. Bone resorption causes more soluble factors to be released into 
the microenvironment, which further fuel the development of metastases in the bone, 
creating a “vicious cycle” of bone resorption and skeletal metastases development. 
Adapted from Sterling et al [3, 45, 46, 60].  
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CSC hypothesis of cancer metastasis [61]. Specifically, the CD44+ stem cell-like 
phenotype has shown increased adherence to human bone marrow endothelial cells in 
breast cancer [62].  
Despite the extensive research conducted in the area of breast cancer metastasis to 
bone, this condition remains incurable. However, bone-targeted therapies do exist that 
attempt to reduce and delay skeletal related events (SREs) such as fractures, spinal cord 
compression and hypercalcaemia. Bisphosphonates were the first agents used clinically to 
reduce SREs and were introduced over three decades ago [63]. There are multiple 
different types of bisphosphonates, including clodronate, ibandronate, pamidronate and 
zoledronic acid; all are structural analogs of inorganic pyrophosphates (PPi) [63, 64]. PPi 
inhibit calcification and bone resorption by incorporating into sites of active bone 
remodeling, binding to hydroxyapatite crystals and inhibiting their breakdown [63]. 
Bisphosphonates also promote osteoclast apoptosis either by becoming incorporated into 
molecules of newly formed adenosine triphosphate (ATP; this nonhydrolyzable analogue 
of ATP is cytotoxic to osteoclasts because it inhibits multiple ATP-dependent processes) 
or by binding to and inhibiting farnesyl pyrophosphate, resulting in the inhibition of the 
posttranslational modification of multiple different proteins essential for osteoclastic 
function [63]. Although bisphosphonates substantially relieve skeletal pain and 
complications in breast cancer patients, absorption in the gastrointestinal tract and 
subsequent localization is poor and use of the drug is with multiple adverse effects 
including osteonecrosis of the jaw, atrial fibrillation, hypocalcaemia and acute 
inflammatory response [63]. More recently, denosomab, a monoclonal antibody that 
binds to RANKL and inhibits its ability to bind to RANK, has been introduced as a 
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therapeutic to reduce SREs. Efficacy and side effects of denosumab are similar to those 
of bisphosphonates and although both drugs are widely used, clinical practice guidelines 
do not specifically state which therapeutic to use over the other [65]. Unfortunately, 
neither bisphosphonates nor denosumab have any effect on progression-free or overall 
survival and are purely palliative in nature [65]. An agent that shows recent promise is 
everolimus, an inhibitor of mammalian target of rapamycin (mTOR); an exploratory 
analysis of the effect of everolimus on bone metastases found that patients using 
everolimus had a significant reduction in bone turnover markers and rates of progressive 
disease [65]. Even if everolimus proves to be useful in clinical applications, breast cancer 
treatment is in dire need of therapeutics that prevent and reduce bone metastases in breast 
cancer patients, rather than just slowing the rate of progression. Elucidation of other 
players within the bone microenvironment that promote the recruitment of breast cancer 
cells to the bone and the establishment of bone metastases is therefore essential to the 
discovery of such therapeutics. 
2.7 Osteopontin 
Osteopontin (OPN) is one of the most abundant non-collagenous extracellular 
matrix proteins in bone and as such, is a protein of interest when considering the bone as 
a favorable niche for breast cancer metastases [66]. OPN is a secreted, acidic 
glycophosphoprotein that was discovered independently multiple times. It was first 
discovered as a 60-kDa malignant transformation-specific phosphoprotein secreted by 
many different tumorigenic cell types, subsequently rediscovered as bone sialoprotein I, a 
major non-collagenous component of the bone extracellular matrix, and then identified as 
a protein associated with T-cell dependent genetic resistance to bacterial infections [67-
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69]. The name “osteopontin” was finally introduced to reflect its inherent ability to form 
bridges between hydroxyapatite (HA) and multiple cell types in bone [70]. OPN is 
expressed by multiple tissues in the body other than bone including the kidney, brain, 
gastrointestinal tract, hypertrophic cartilage, dentin and cementum. However the highest 
levels of the protein in a healthy human body are associated with mineralized tissues and 
bodily fluids that have high concentrations of calcium, such as breast milk, urine and 
seminal fluid [71, 72]. In the bone, OPN is produced by osteoblasts, osteoclasts, 
osteocytes and macrophages [66, 73]. Human OPN can range in size from 41- to 75-kDa 
due to the myriad of post-translational modifications it undergoes, including 
phosphorylation, glycosylation, proteolytic cleavage and crosslinking by 
transglutamination [73]. Its structure consists of various highly conserved regions that are 
indicative and essential to its various biological functions [72, 73] (Figure 3). It contains 
a calcium binding motif and many electronegative glutamic and aspartic acid residues 
that allow it to tightly bind to HA in bone. Binding of OPN to HA renders it a potent 
inhibitor of mineralization, as it inhibits the growth of HA crystals. It also has RGD 
(arginine-glycine-aspartate) and SVVYGLR (serine-valine-valine-tyrosine-glycine-
leucine-arginine) domains for integrin binding and a heparin binding site that mediates 
CD44 receptor binding [73, 74]. The ability of OPN to bind to cells that express cell 
surface receptors such as integrins and CD44 allows it to mediate cell attachment, cell 
migration, chemotaxis and intracellular signaling in various cell types, including 
monocytic cells/macrophages, smooth muscle cells, endothelial cells and epithelial cells 
[75].   
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Figure 3. Osteopontin Protein Structure 
OPN contains a number of highly conserved structural features that are indicative of its 
biological functions. It contains a thrombin cleavage domain, which results in proteolytic 
cleavage and of OPN into two similarly-sized fragments. The N-terminal fragment 
contains as aspartate rich domain which allows OPN to bind hydroxyapatite in bone. The 
RGD and SVVYGLR domains allow for binding to ligands expressing RGD-dependent 
integrins (αvβ1, αvβ3, αvβ5, α5β1) as well as SVVYGLR-dependent integrins (α4β1, 
α9β1). The C-terminal fragment contains two heparin binding domains which assist in the 
binding of OPN to CD44 and a calcium binding domain. Adapted from Tuck et. al (2003) 
[76].  
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OPN expression is observed in many pathophysiological responses and 
pathological conditions, including cardiovascular disease (e.g. atherosclerosis, and 
ventricular hypertrophy), kidney diseases (e.g. kidney stone formation), wound healing, 
fibrosis, autoimmune diseases and multiple different cancers [72, 73, 75]. Its presence in 
traumatized, diseased and inflamed tissues can be accounted for by heavy secretion from 
activated macrophages and T-lymphocytes. In these settings, OPN promotes adhesion of 
T-cells and contributes to type-1 cell mediated immunity by modulating macrophage 
interleukin expression.  
OPN’s role in malignancy is well documented; it is secreted by several types of 
cancer cells including breast, lung, gastric, ovarian and myeloma cancer cells [77-81]. In 
these cancers, it has been shown to mediate cell-matrix and cell-cell communication 
through interactions with a variety of cell surface receptors (i.e. CD44, α9β1, αvβ3 and 
αvβ5) to activate pathways that contribute to multiple steps in the metastatic cascade [82-
87]. Firstly, OPN can protect cells against apoptosis and induce survival and proliferation 
via in multiple ways, including through NK-κB downstream of the αvβ3 cell surface 
integrin, the PI3K-Akt axis downstream of CD44 or via epidermal growth factor (EGF)-
dependent mechanisms [75]. It has been shown that breast carcinoma cells are protected 
against apoptosis when they adhere to OPN via αvβ3 [88]. Studies have also shown that 
OPN can induce angiogenesis by up-regulating vascular endothelial growth factor 
(VEGF) expression through the activation of PI3K/Akt and ERK-mediated pathways. 
OPN also has a direct effect on cancer cell migration via CD44 and RGD-dependent cell 
surface integrins; it has been shown to induce migration via growth factor pathways 
involving hepatocyte growth factor (HGF), its receptor Met and epidermal growth factor 
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(EGF), as well as interact with focal adhesion complexes to impact cell motility [83]. 
OPN signaling via αvβ3 also induces uPA and multiple types of MMP secretion by breast 
cancer cells that allows them to invade through the basement membrane.  
In the establishment of bone metastases specifically, OPN assists in the 
attachment of breast cancer cells to human bone marrow endothelial cells and thus plays 
a vital role in the early steps of bone colonization [83]. It also contributes to the up-
regulation of bone resorption during breast cancer metastasis to bone as neutralization of 
OPN can suppress osteoclastogenesis, whereas addition of OPN enhances 
osteoclastogenesis by up-regulating RANKL and decreasing osteoprotegerin (OPG), an 
osteoclastogenesis inhibitory factor. OPN’s role as a metastasis-enhancing protein is 
supported by the observation that OPN-deficient mice have a reduced number of 
metastases to bone and soft tissue [89]. OPN can also generate a favorable growth 
environment for breast cancer cells in bone by activating a variety of growth factors, 
including HGF, TGF-β and bFGF via the upregulation of µPA and IL-11 [83].  
OPN has been identified as a clinical prognostic marker; clinical studies have 
revealed a correlation between elevated plasma OPN levels, increased tumor burden and 
poor prognosis in cancer patients [83, 84]. The amount of plasma OPN in healthy women 
ranges from 22 to 122 µg/L, with a median level of 47 µg/L. A higher level of OPN, 
upwards of 300 µg/L, exists in the plasma of breast cancer patients as well as colon, lung 
and prostate cancer patients [83, 84, 90]. In breast cancer specifically, high levels of OPN 
in carcinoma cells are associated with increased metastases to the bone [91]. Although 
extensive research has demonstrated that tumor-derived OPN can contribute to several 
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steps of the metastatic cascade, the role of bone-derived OPN in the metastatic 
progression of breast cancer has yet to be fully investigated.  
2.8 Project Rationale 
Extensive work has focused on characterizing the role of the bone 
microenvironment in breast cancer metastasis in hopes that this knowledge would lead to 
the discovery of clinically applicable agents that could prevent, reduce and slow the 
growth of bone metastases in breast cancer patients. However, there remain unanswered 
questions regarding the mechanism in which the bone niche promotes the establishment 
of breast cancer bone lesions remains unclear. Further work must be done in order to 
characterize what makes the bone a suitable “soil” for breast cancer cells, and identifying 
soluble factors in bone marrow that contribute to breast cancer cell recruitment and 
establishment of metastatic lesions is necessary in this regard. Previous work by Jenny 
Chu in the Allan lab lead to the establishment of a comprehensive ex vivo model system 
for investigating the influence of organ-specific soluble factors on the metastatic behavior 
of breast cancer cells (described in further detail below) [92]. Preliminary work indicated 
that both whole population and stem-like ALDHhiCD44+CD44- breast cancer cells show 
enhanced migration towards bone marrow conditioned-media relative to control [92]. The 
goal of the current project is to investigate the role of bone-derived OPN in the migration 
and stem-like behavior of whole population and ALDHhiCD44+CD24- breast cancer cells 
in bone.  
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3 HYPOTHESIS and OBJECTIVES 
 
3.1 Hypothesis 
Bone-derived OPN promotes the migration and stem-like behavior of breast 
cancer cells. 
 
3.2 Objectives 
1. To determine the role of bone-derived OPN in promoting breast cancer migration and 
stem-like behavior of breast cancer cells.  
2. To investigate the receptor-ligand interactions between breast cancer cells and bone-
derived OPN and the functional consequences on migration and stem-like behavior.  
3. To assess the OPN-associated downstream signaling responses within breast cancer 
cells in response to bone-conditioned media. 
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4 MATERIALS and METHODS 
 
4.1 Cell Culture and Reagents 
MDA-MB-231 cells [93] were obtained from American Type Culture Collection 
(Manassas, VA) and maintained in DMEM/F12+10% fetal bovine serum (FBS). 
SUM159 cells [94] were obtained from Asterand Inc. (Detroit, MI) and maintained in 
HAMS:F12 + 5% FBS + 5 µg/mL insulin + 1 µg/mL hydrocortisone + 10mM HEPES. 
Media/supplements were from Invitrogen (Carlsbad, CA); FBS was from Sigma-Aldrich 
(St. Louis, MO). 
4.2 Bone Marrow-Conditioned Media (BMCM) 
Bone marrow-conditioned media (BMCM) was generated as previously described 
[92]. Briefly, healthy female nude mice (Hsd: Athymic Nude-Foxn1nu; Harlan Sprague-
Dawley, Indianapolis, IN) were maintained as per the Canadian Council of Animal Care 
(CCAC) under a protocol approved by the Western University Animal Use 
Subcommittee (AUS; #2009-064). Mice (6-12 weeks old) were euthanized and bone 
marrow was collected by flushing femur cavities as previously described [95]. Aspirates 
were dissociated by pipetting and cells were washed and plated in DMEM + 10% FBS + 
pen/strep. Resulting adherent bone marrow stromal cells (BMSCs) were passaged 2-3 
times, washed, and exposed to DMEM/F12 + Mito+™ + pen/strep. Conditioned media 
was collected after 72 hr and stored at -20oC. To account for mouse-to-mouse variability, 
BMCM from multiple mice was pooled prior to use.  
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4.3 RayBio® Biotin Label-Based Mouse Antibody Arrays 
The Raybio® Biotin label-based mouse antibody array (AAM, BLM-1, 
RayBiotech Inc, Norcross, GA) were used to assess the expression of 308 murine soluble 
factors within BMCM. Basal media samples (DMEM/F12 + Mito+™ + pen/strep) or 
BMCM protein samples (0.12 mg each) were dialyzed and labeled with a biotin-labeling 
reagent. Free biotin was removed using spin columns, membranes were blocked and 
samples were added to the membranes and incubated at 4oC overnight. Streptavidin-
horseradish peroxidase (HRP) and chemiluminescent detection reagents were used to 
produce a signal at each capture spot corresponding to the amount of protein bound. 
Membranes were visualized using ChemiDoc Detection Software (n=3 for each media 
condition) (BioRad, Hercules, CA). The concentration of resulting proteins of interest 
present in BMCM was confirmed by Quantkine ELISA (R&D Systems, Minneapolis, 
MN). 
4.4 Immunodepletion of OPN 
Osteopontin was immunodepleted from BMCM using a rat anti-mouse 
osteopontin-specific antibody (R&D Systems). Antibodies were incubated for 20 minutes 
at RT with Dynabeads Protein G (8 µg OPN-specific antibody per mg of beads; Life 
Technologies, Burlington, ON). Bead-antibody complexes were then incubated with 
BMCM for 30 minutes at RT. Resulting bead-antibody-antigen complexes were removed 
from BMCM using a DynaMag-2 magnet (Life Technologies). The concentration of OPN 
in depleted BMCM was assessed by Quantikine ELISA kits specific for OPN (R&D 
Systems). Negative controls included BMCM exposed to beads only (no antibody). GST-
tagged human OPN (GST-hOPN), a kind gift from Dr. Ann Chambers, London Regional 
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Cancer Program, London, Ontario, is a functional representative of native OPN [85]. For 
rescue experiments, GST-hOPN was added back to BMCM depleted of OPN at the same 
concentration that was originally depleted from BMCM.   
4.5 Migration Assays 
Transwells® (6.5 mm, 8 µm pore size; Falcon, Corning, NY) were coated with 6 
µg of gelatin per well. Osteopontin-depleted or non-depleted BMCM or basal media 
(DMEM/F12 + Mito+™) were placed in 24-well dishes (n = 3 per condition). MDA-MB-
231 or SUM-159 cells (5 x 104 cells per well) were plated on top of the gelatin-coated 
Transwells®, then inserted into 24-well dishes. In experiments involving functional 
blocking of CD44 or RGD (Arginin-Glycine-Aspartic acid)-sequences, cells were 
incubated for 30 minutes at RT with a rat anti-human CD44 antibody (10 µg/5 x 105 cells, 
Calbiochem, Mississauga, ON) or an RGD-sequence specific peptide (50 µg/5 x 105 cells 
for MDA-MB-231 breast cancer cells, 100 µg/5 x 105 cells for SUM-159 breast cancer 
cells; Sigma-Aldrich). After 18 hours incubation at 37°C and 5% CO2, Transwells® were 
removed, fixed and non-migrated cells were removed from the inner surface of the 
Transwell®. Membranes were then carefully cut from the rest of the Transwell® and 
migrated cells were stained with DAPI. Five high-powered fields (HPFs) of view were 
counted for each membrane using ImageJ [National Institutes of Health (NIH), Bethesda, 
MD] software. Results are expressed as a fold-increase from negative control (n = 3).  
4.6 Sphere-Limiting Dilution Assays (SLDA) and Colony-
Forming Assays 
MDA-MB-231 cells were seeded in 96-well plates for colony-forming assays 
(Corning, Lowell, Massachusetts) or 96-well ultra-low attachment plates (Corning) for 
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the sphere-limiting dilution assay (SLDA) in a serial-diluted fashion ranging from 1000 
cells/well to 0.001 cells/well. In experiments involving functional blocking, and anti-
CD44 antibody (10 µg/5 x 105 cells; Calbiochem) or an RGD-sequence specific peptide 
(50 µg/5 x 105 cells; Sigma-Aldrich) were used in a similar fashion as in the TranswellTM 
migration assays. Osteopontin-depleted or non-depleted BMCM or basal media 
(DMEM/F12 + MITO+™) was added to the wells and cells were incubated with control 
media or conditioned media for 5 days at 37°C and 5% CO2. After incubation, each well 
was scored for the presence or absence of colonies (n = 3) or tumorspheres (n = 3) using 
L-Calc™ Software (Stem Cell Technologies, Vancouver, British Columbia).  
4.7 Flow Cytometry 
Cells were grown to 80% confluence in normal growth media, harvested and 
resuspended at 1 x 106 cells/ml. Cells were then incubated with phycoerytherin (PE)-
conjugated CD44 (BD Biosciences, San José, CA), fluorescein isothiocyanate (FITC)-
conjugated αvβ3 (R&D Systems), Alexafluor (AF)-488-conjugated αvβ5 (R&D 
Systems), AF-488-conjugated β1 (R&D Systems) or AF-488-conjugated α9β1 (R&D 
Systems) antibodies for 1 hour at 4°C. Negative controls included cells only (no 
antibody) and cells incubated with an isotype-matched IgG-control. Samples were run on 
a Beckman-Coulter EPICS XL-MCL flow cytometer.  
4.8 Fluorescence-Activated Cell Sorting (FACS) 
ALDHhiCD44+CD24- and ALDHloCD44-CD24+ cell subpopulations were isolated 
from the MDA-MB-231 breast cancer cell line as previously described [33, 34]. Briefly, 
cells were concurrently labeled with 7-amino-actinomycin D (7-AAD), ALDEFLUORTM 
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assay kit (StemCell Technologies; Vancouver, BC) (Figure 4) and fluorescently-
conjugated antibodies including anti-CD44 (clone IM7) conjugated to allophycocyanin 
(APC) and anti-CD24 (clone ML5) conjugated to phycoerytherin (PE) (BD Biosciences). 
ALDH activity was used as the primary sort criteria (top ~20%=ALDHhi; bottom 
~20%=ALDHlow) and the CD44+CD24- phenotype as the secondary sort criteria (top 
~10% gated on ALDHhi; bottom ~10% gated on ALDHlow) (Figure 5). Cell viability was 
assessed by 7-AAD staining during cell sorting, and confirmed by trypan blue exclusion 
post-sorting. FACS-isolated cells were used immediately for in vitro assays.   
4.9 Human Phospho-Kinase Array 
MDA-MB-231 cells were incubated in basal media, BMCM and BMCM depleted 
of OPN and cell lysates were harvested after 2 hr. Protein concentrations were 
determined with a BioRad DC protein assay (BioRad) and 400 µg of cell lysates were 
incubated with the Human Phospho-Kinase Array membranes (ARY003B, R&D 
Systems) overnight at 4°C. According to the manufacturer’s instructions and using kit 
contents, arrays were washed to remove unbound proteins and a cocktail of biotinylated 
detection antibodies was applied. Streptavidin-HRP and chemiluminescent detection 
reagents were used to produce a signal at each capture spot corresponding to the amount 
of phosphorylated protein bound. Membranes were visualized using ChemiDoc Detection 
Software (BioRad). Densitometry analysis was performed using the Protein Array 
Analyzer for ImageJ (n = 3 for each media condition) [96].  
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Figure 4. Mechanism of the ALDEFLUORTM assay (StemCell Technologies) 
The ALDEFLUORTM assay is used to identify cells that demonstrate activity of the 
enzyme aldehyde dehydrogenase. The assay uses a fluorescent, non-toxic reagent, 
BODIPYTM-aminoacetylaldehyde (BAAA) that can diffuse freely into viable cells. 
BAAA is a substrate for ALDH and is converted into BODIPYTM-aminoacetate (BAA-), 
which is retained in the cell due to its negative charge. The active removal of BAA- is 
inhibited with the use of cold ALDEFLUORTM assay buffer. The resulting fluorescence 
of the cell is assessed by flow cytometry. Diethylaminobenzaldehyde (DEAB) is used as 
a negative control because of its ability to inhibit the activity of ALDH; when DEAB is 
used, the intrinsically neutral BAAA is free to passively diffuse back out of the cell. The 
fluorescence of the DEAB-treated cells are used to create the gate for the ALDHhi cells. 
Adapted from Chu and Allan (2011) [18].  
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Figure 5: Strategy for isolation of MDA-MB-231 ALDHhiCD44+CD24- and 
ALDHloCD44-CD24+ breast cancer cells. 
MDA-MB-231 cells are labeled with 7-AAD, CD44-APC, CD24-PE and the 
ALDEFLUORTM assay kit. Cell subsets are isolated using a four-colour protocol on a 
FACS ARIA III. (A) Cells are first isolated based on expected light scatter and then (B) 
viability based on 7-AAD exclusion. Cells are then analyzed for (C) ALDH activity; the 
top 20% most positive for ALDH activity are deemed ALDHhi and the bottom 20% for 
ALDH activity are deemed ALDHlo. Then, (D) ALDHhi cells are selected for the 
CD44+CD24- phenotype (top 50%) and (E) ALDHlo cells are selected for the CD44-
/lowCD24+ phenotype (bottom 50%).  
 
FACSDiva Version 6.1.3
MDA MB 231 Printed on: Fri May 23, 2014 04:19:50 PDT
A
FACSDiva Version 6.1.3
MDA MB 231 Printed on: Fri May 23, 2014 04:20:01 PDT
B
FACSDiva Version 6.1.3
MDA MB 231 Printed on: Fri May 23, 2014 04:20:01 PDT
FACSDiva Version 6.1.3
MDA MB 231 Printed on: Fri May 23, 2014 04:20:01 PDT
FACSDiva Version 6.1.3
MDA MB 231 Printed on: Fri May 23, 2014 04:20:01 PDT
C
D
E
30 
 
4.10 Data Analysis 
In vitro experiments were performed a minimum of three times with three 
technical replicates within each experiment. Unless otherwise noted, all data are 
presented as the mean ± standard error of the mean (SEM). Statistical analysis was 
performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA) using one-
way analysis of variance (ANOVA) with Tukey’s or Bonferroni’s post-hoc tests. Values 
of p<0.05 were classified as being statistically significant. 
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5 RESULTS 
 
5.1 Bone marrow-conditioned media contains multiple soluble 
factors that could contribute to breast cancer’s affinity for 
bone 
Assessment of soluble factors present in bone marrow-conditioned media 
(BMCM) was carried out using the RayBio® Biotin Label-Based Mouse Antibody Array 
(AAM, BLM-1, RayBiotech Inc), a protein array that tests for the presence of 308 soluble 
factors of interest. Of the proteins identified in BMCM using the protein array (Figure 6), 
five were found to be associated with steps of the metastatic cascade (Table 1). Of these, 
three soluble factors of interest, osteopontin (OPN), matrix metalloproteinase-14 (MMP-
14) and insulin-like growth factor-2 (IGF-2) were chosen for further functional validation 
based on evidence in the literature of their possible involvement in cancer migration and 
growth.  
5.2 Bone-derived OPN promotes human breast cancer cell 
migration 
OPN, MMP-14 and IGF-2 concentrations were analyzed in BMCM samples with 
Quantikine® ELISA. IGF-2 concentrations were observed to be minimal (below 30 
pg/mL) in BMCM samples tested (data not shown). However, OPN and MMP-14 were 
observed to be present in BMCM samples tested. To assess the effect of bone-derived 
OPN and MMP-14 on human breast cancer cell migration, OPN was depleted from 
BMCM using Dynabeads® Protein G (Novex by Life Technologies) and depletion 
efficiency was confirmed with a Quantikine ELISA (R&D Systems)  
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Figure 6. Bone marrow-conditioned media contains potential mediators of 
metastasis 
The Raybio® Biotin label-based mouse antibody array (AAM, BLM-1, RayBiotech Inc) 
was used to identify soluble factors present in BMCM. Membranes were incubated with 
biotinylated samples of (A) basal media or (B) BMCM at 4oC overnight and visualized 
using chemiluminescence. Dotted boxes indicate internal positive controls, lined boxes 
indicate internal negative controls and solid boxes indicate proteins of interest that are 
potentially involved in the metastatic cascade.  
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Table 1: Metastasis-associated proteins identified in bone marrow-conditioned 
media with the RayBio® Biotin label-based mouse antibody array 
Location	  on	  Array	  
(Figure	  6) 
Protein	  Name Function/Involvement in	  
Malignancy 
References 
39 Basic Fibroblast 
Growth Factor 
(bFGF) 
• Overexpressed in breast cancer 
patients 
• Implicated in osteoblastic bone 
metastases 
• Regulates neoplastic cell growth 
 
[90,	  97] 
158 Intracellular 
Adhesion 
Molecule-1 
(ICAM-1) 
• Elevated in metastatic breast 
cancer patients 
• Downregulation leads to a strong 
suppression of breast cancer cell 
invasion  
 
 
[98] 
176 Insulin-Like 
Growth Factor-2 
(IGF-2) 
• Up-regulated in triple-negative 
breast cancer 
• Down-regulation of bone-
derived IGF-2 suppresses the 
growth of bone metastases in 
prostate cancer 
 
[99,	  100] 
326 Matrix-
Metalloproteinase-
14 (MMP-14) 
• Modulates migratory ability of 
breast cancer cells 
• High levels of MMP-14 correlate 
with bone metastases  
 
[101,	  102] 
333 Osteopontin 
(OPN) 
• Most abundant extracellular 
matrix protein in the bone  
• Associated with multiple steps of 
the metastatic cascade, including 
proliferation, migration, 
adhesion and invasion 
[83,	  84,	  90] 
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(Figure 7A). However, MMP-14 could not be successfully depleted from BMCM using 
Dynabeads® Protein G and available MMP-14 antibodies (data not shown), thus MMP-14 
was no longer pursued. The TranswellTM migration assay was then used to assess the 
migration of MDA-MB-231 and SUM-159 cells to basal media, BMCM and BMCM 
depleted of OPN. These two breast cancer cell lines were chosen since the Allan lab has 
previously shown that they both display increased migration toward BMCM [92]. Both 
cell lines exhibited increased migration toward BMCM compared to basal media (P< 
0.05, Figure 7B,C) and exhibited significantly decreased migration to BMCM depleted of 
OPN (P< 0.05, Figure 7). In fact, the depletion of OPN from BMCM decreased the 
migration of both cells lines to a level not significantly different than basal media 
(P>0.05; Figure 7B,C). To validate that bone-derived OPN was specifically responsible 
for the observed effects on breast cancer cell migration, recombinant human OPN (GST-
hOPN) was added back into BMCM depleted of OPN at the same concentration 
originally depleted from the BMCM. The addition of GST-hOPN to BMCM rescued the 
migratory effect of both MDA-MB-231 and SUM-159 cells, causing cells to migrate to 
similar levels as to non-depleted BMCM (Figure 7B,C). These results demonstrate that 
bone-derived OPN mediates breast cancer cell migration towards BMCM. 
5.3 Bone-derived OPN promotes stem-like behavior of breast 
cancer cells 
We next wanted to investigate if bone-derived OPN mediates the stem-like 
behavior of breast cancer cells, since the stem-like subpopulation of breast cancer cells 
has been shown to play a role in the metastatic process. We used a sphere limiting 
dilution assay (SLDA) to assess the effect of bone-derived OPN on the tumorsphere-
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forming capacity of breast cancer cells. The SLDA tests the ability of cells to form 
tumorspheres in vitro, a marker for cell “stemness”. Whole population MDA-MB-231 
cells show increased tumorsphere-forming capacity in BMCM compared to basal media 
(P<0.05, Figure 8A). This tumorsphere- 
 
Figure 7. Bone-derived OPN promotes the migration of MDA-MB-231 and SUM-
159 human breast cancer cells 
(A) Goat anti-mouse OPN primary antibody was incubated for 20 min at RT with 
DynaBeads® Protein G (EMD Millipore) prior to addition and incubation with BMCM for 
30 min at RT. The beads-antibody-antigen complex was removed with a DynaMag™-2 
magnet. Concentration of OPN in BMCM, BMCM with Dynabeads® only (no antibody) 
and BMCM depleted of OPN (ΔOPN) was tested with Quantikine® ELISA (R&D 
Systems). Significance determined by one-way ANOVA and Tukey’s post-hoc test. (B) 
MDA-MB-231 and (C) SUM-159 human breast cancer cells were plated on gelatin 
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coated TranswellsTM (5 x 104 cells/well; 8µm pore size) before placement into either 
basal media (DMEM/F12 + Mito+), BMCM, BMCM ΔOPN or BMCM ΔOPN with GST-
hOPN added. Plates were incubated at 37oC at 5% CO2 for 18 hr. TranswellsTM were then 
fixed with 1% gluteraldehyde and stained with DAPI. Five high-powered fields of view 
(HPFs) were captured/TranswellTM and migrated cells were enumerated through the use 
of ImageJ software (NIH). Data are presented as mean ± SEM (N = 3; fold change from 
negative control of basal media). Significance determined with one-way ANOVA and 
Tukey’s post-hoc test;* = significantly different from basal media; ϕ = significantly 
different from BMCM; δ = significantly different from BMCM ΔOPN: P< 0.05.   
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forming capacity decreases when BMCM is depleted of OPN (P<0.05, Figure 8A), 
suggesting that bone-derived OPN mediates this function in MDA-MB-231 cells. We 
also investigated the role of bone-derived OPN in the limiting dilution colony-forming 
ability of MDA-MB-231 cells. Whole population MDA-MB-231 cells show increased 
colony-forming abilities in BMCM compared to basal media (P<0.05, Figure 8B). When 
cells are exposed to BMCM depleted of OPN, their colony-forming capacity decreases 
significantly (P≤0.05, Figure 8B), suggesting that bone-derived OPN also plays a role in 
the colony-forming ability of breast cancer cells in a limiting dilution fashion. 
As previously discussed, stem-like ALDHhiCD44+CD24- breast cancer cells are 
important mediators of metastasis to multiple different organs, including bone [17, 34]. 
We therefore also investigated if bone-derived OPN mediates the stem-like phenotype of 
these breast cancer cells. We have previously shown that this subpopulation of MDA-
MB-231 cells is responsible for the increased migration to BMCM, compared to their 
non-stem like ALDHloCD44-CD24+ cells [92]. Thus, we first investigated if bone-derived 
OPN influenced the migration of this stem-like population. We observed that FACS-
isolated ALDHhiCD44+CD24- cells showed significantly increased migration toward 
BMCM compared to basal media (P<0.05, Figure 8C). When OPN is depleted from 
BMCM, the ALDHhiCD44+CD24- subpopulation shows decreased migration, suggesting 
that bone-derived OPN influences the migration of these stem-like cells. The non stem-
like ALDHloCD44-CD24+ cells did not display significantly increased migration to 
BMCM or BMCM depleted of OPN compared to basal media (P>0.05, Figure 8C), as 
expected from our previous work [34, 92]. We also observed that the tumorsphere-
forming capacity of ALDHhiCD44+CD24- breast cancer cells decreases in BMCM  
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Figure 8. Bone-derived OPN promotes the stem-like behavior of MDA-MB-231 
breast cancer cells 
Whole population MDA-MB-231 cells were plated in a limiting dilution fashion for 7 
days in basal media (DMEM/F12 + Mito+), BMCM or BMCM ΔOPN on (A) ultra-low 
adhesion 96-well plates for sphere-limiting dilution assays or (B) on a normal 96-well 
plates for limiting dilution colony-forming assays. (C) FACS-isolated 
ALDHhiCD44+CD24- or ALDHloCD44-CD24+ cells from the MDA-MB-231 cell line 
were plated on gelatin-coated Transwells® (5 x 104 cells/well; 8µm pore size) before 
placement into either basal media (DMEM/F12 + Mito+), BMCM or BMCM ΔOPN. 
Plates were incubated at 37oC at 5% CO2 for 18 hr. TranswellsTM were then fixed with 
1% gluteraldehyde and stained with DAPI. Five high-powered fields of view (HPFs) 
were captured/Transwell® and migrated cells were enumerated with ImageJ software 
(NIH) (D) FACS-isolated ALDHhiCD44+CD24- and ALDHloCD44-CD24+ cells were also 
used in the SLDA as in (A). Data are presented as mean ± SEM (N = 3; fold change from 
negative control of basal media). Significance (P< 0.05) was determined with one-way 
ANOVA and a Bonferroni’s post-hoc test (SLDA and colony formation) or a Tukey’s 
post-hoc test (migration); * = significantly different from basal media; ϕ = significantly 
different from BMCM; δ = significantly different from BMCM ΔOPN.  
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depleted of OPN compared to BMCM (P<0.05, Figure 8D), suggesting that these stem-
like cells are responsible for the tumorsphere-forming capacity of MDA-MB-231 cells in 
BMCM and that bone-derived OPN may mediate this.  
5.4 Breast cancer cell migration promoted by bone-derived OPN 
is mediated by CD44 and RGD-dependent cell surface 
integrins 
In order to investigate the mechanism by which bone-derived OPN promotes the 
migration of breast cancer cells in BMCM, we chose to explore the functional role that 
select cell surface receptors play in this interaction. OPN is known to influence multiple 
steps in the metastatic cascade through the cell surface receptor CD44, as well as multiple 
different cell surface integrins, including αvβ1, α9β1 αvβ3 and αvβ5 [83]. Thus, we first 
evaluated the expression of CD44, β1, α9β1 αvβ3 and αvβ5 on the MDA-MB-231 and 
SUM-159 cell lines. Flow cytometry indicated that both cell lines are positive for the 
expression of CD44 and these four cell surface integrins (Figures 9 and 10).  
Next, we investigated the role of these cell surface receptors on the migration of 
breast cancer cells using an anti-CD44 functional blocking antibody (Calbiochem) or the 
Arg-Gly-Asp (RGD) peptide (Sigma-Aldrich). OPN contains an RGD recognition 
sequence that is recognized by a number of cell surface integrins, including the ones 
examined; therefore incubating the cells with the RGD-sequence specific peptide prior to 
use in functional assays should block the recognition of OPN via the RGD sequence [85, 
103]. We observed that blocking CD44 on the MDA-MB-231 and SUM-159 cells 
significantly decreases migration to BMCM compared to migration of untreated cells (P< 
0.05, Figure 11A, 11C). The migration of CD44-blocked MDA-MB-231 to BMCM was 
reduced to a level similar of untreated cells to BMCM depleted of OPN, suggesting that  
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Figure 9. MDA-MB-231 cells express OPN receptors including CD44 and multiple 
different cell surface integrins. 
Representative histograms are shown from flow cytometry characterization of MDA-
MB-231 cells incubated with (A) phycoerytherin-conjugated anti-CD44, (B) AlexaFluor-
488-conjugated anti-integrin β1, (C) fluorescein isothiocyanate-conjugated anti-integrin 
αvβ3, (D) AlexaFluor-488 anti-integrin αvβ5 or (E) AlexaFluor-488 conjugated anti-
integrin α9β1 antibodies (black) for 1hr at 4°C compared to cells incubated with an 
isotype-matched IgG-control (white). Samples were analyzed on a Beckman-Coulter 
EPICS XL-MCL flow cytometer.  
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Figure 10. SUM-159 cells express OPN receptors including CD44 and multiple 
different cell surface integrins. 
Representative histograms are shown from flow cytometry characterization of SUM-159 
cells cells incubated with (A) phycoerytherin-conjugated anti-CD44, (B) AlexaFluor-
488-conjugated anti-integrin β1, (C) fluorescein isothiocyanate-conjugated anti-integrin 
αvβ3, (D) AlexaFluor-488 anit-integrin αvβ5 or (E) AlexaFluor-488 conjugated anti-
integrin α9β1 antibodies (black) for 1hr at 4°C compared to cells incubated with an 
isotype-matched IgG-control (white). Samples were analyzed on a Beckman-Coulter 
EPICS XL-MCL flow cytometer. 
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Figure 11. Promotion of breast cancer cell migration by bone-derived OPN is 
mediated by the cell surface receptor CD44 and various RGD-dependent cell 
surface integrins    
(A) MDA-MB-231 and (B) SUM-159 cells were blocked with an anti-CD44 antibody for 
30 min and plated on gelatin coated TranswellsTM (5 x 104 cells/well; 8µm pore size) 
before placement into basal media (DMEM/F12 + Mito+), BMCM or BMCM ΔOPN. 
Plates were incubated at 37oC at 5% CO2 for 18 hr. TranswellsTM were then fixed with 
1% gluteraldehyde and stained with DAPI. Five high-powered fields of view (HPFs) 
were captured/TranswellTM and the migrated cells were enumerated through the use of 
ImageJ software (NIH). (C) MDA-MB-231 and (D) SUM-159 cells were blocked with an 
RGD sequence-specific peptide for 30 min and used in the TranswellTM migration assay 
as described above. Data are presented as mean ± SEM (N = 3; fold change from 
negative control of basal media). Significance was determined with one-way ANOVA 
and Tukey’s post-hoc test;.* = significantly different from basal media; ϕ = significantly 
different from BMCM; δ = significantly different from BMCM ΔOPN: P< 0.05.   
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CD44 is responsible for the effect of bone-derived OPN of breast cancer cell migration 
(P>0.05, Figure 11A). In contrast, CD44-blocked SUM-159 cell migration to BMCM 
was significantly lower than untreated SUM-159 cell migration to BMCM depleted of 
OPN (P< 0.05, Figure 11C). This suggests that CD44 may mediate the interaction of 
SUM-159 with bone-derived OPN as well as other, as yet uninvestigated soluble CD44-
ligands within the BMCM. 
Our results also indicate that blocking the RGD-recognition sequence on MDA-
MB-231 and SUM-159 cells significantly reduces the migration to BMCM compared to 
migration of untreated cells (P<0.05, Figure 11B, 11D). RGD-blocked MDA-MB-231 
cells showed significantly decreased migration to BMCM compared to untreated cells to 
BMCM depleted of OPN (P<0.05, Figure 11B). These results suggest that RGD-
dependent integrins may mediate the interaction of MDA-MB-231 with bone-derived 
OPN and other soluble factors that interact with integrins within the BMCM. In contrast, 
RGD-blocked SUM-159 cells showed similar migratory levels to BMCM as untreated 
cells to BMCM depleted of OPN, suggesting that RGD-dependent cell surface integrins 
mediate the interaction of SUM-159 cells with bone-derived OPN (P>0.05, Figure 8D).  
5.5 Promotion of breast cancer stem-like behavior by bone-
derived OPN is mediated through CD44 and RGD-dependent 
cell surface integrins 
 Given that CD44 and RGD-dependent integrins mediate the interaction between 
breast cancer cells and bone-derived OPN to influence migration to BMCM, we wanted 
to explore if these cell surface receptors also influence the stem-like behaviour of breast 
cancer cells in response to bone-derived OPN. An anti-CD44 blocking antibody 
(CaliBiochem) and RGD-sequence specific peptide (Sigma Aldrich) were used to block 
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MDA-MB-231 in the SLDA. Both CD44-blocked and RGD-blocked MDA-MB-231 cells 
showed decreased tumorsphere-forming capacity when exposed to BMCM and BMCM 
depleted of OPN compared to untreated cells exposed to BMCM depleted of OPN 
(P<0.05, Figure 12A, 12B), suggesting that both CD44 and RGD-dependent integrins can 
mediate the tumorsphere-forming capacity of breast cancer cells.   
5.6 Bone-derived OPN causes phosphorylation changes in 
migratory and stem-like related pathways in breast cancer 
cells 
We have shown that bone-derived OPN influences the migratory ability and stem-
like behavior of breast cancer cells via CD44 and RGD-dependent cell surface integrins. 
Considering this, we wanted to begin to investigate the effect of bone-derived OPN on 
downstream pathways within breast cancer cells. For this, we used the Human Phospho-
Kinase Array (R&D Systems), which simultaneously detects the relative site-specific 
phosphorylation of 43 kinases and upregulation of 2 related total proteins. We exposed 
MDA-MB-231 cells to basal media ((DMEM/F12 + MITO+), BMCM and BMCM 
depleted of OPN for 2 hr prior to harvesting cell lysates for use with the array. Figure 13 
shows 15 different kinases and 1 protein that were shown to be significantly different 
between treatments. Results show that BMCM causes the up-regulation of WNK-1, 
PRAS40 and HSP60, compared to basal media (P≤0.05; Figure 13) and BMCM depleted 
of OPN (P≤0.05; Figure 13). Table 2 includes further details about these proteins of 
interest. We are currently in the process of validating these findings by immunoblotting. 
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Figure 12: Promotion of breast cancer cell tumorsphere-forming capacity by bone-
derived OPN is mediated by the cell surface receptor CD44 and various RGD-
dependent cell surface cell surface integrins  
MDA-MB-231 human breast cancer cells were blocked with (A) anti-CD44 antibodies or 
(B) an RGD sequence-specific peptide for 30 minutes prior to plating in a limiting 
dilution fashion on ultra-low adhesion 96-well plates for 7 days in basal media 
(DMEM/F12 + Mito+), BMCM or BMCM Δ OPN in the sphere-limiting dilution assay. 
Significance determined with a two-way ANOVA and a Bonferroni’s post-hoc test; * = 
significantly different from basal media; ϕ = significantly different from BMCM; δ = 
significantly different from BMCM ΔOPN: P< 0.05.  
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Figure 13. Bone-derived OPN causes phosphorylation changes in migration- and 
stem cell-related signaling pathways in breast cancer cells 
MDA-MB-231 human breast cancer cells were incubated in basal media, BMCM or 
BMCM ΔOPN and cell lysates were harvested after 2 hr. Cell lysates were incubated 
with the Human Phospho-Kinase Array membranes (ARY003B, R&D Systems) 
overnight at 4°C. Biotinylated detection antibodies were applied and membranes were 
visualized using chemiluminescence. Densitometry analysis was performed using the 
Protein Array Analyzer for ImageJ and significance (P<0.05) was determined with a 
Tukey’s test; * = significantly different from basal media; ϕ = significantly different from 
BMCM; δ = significantly different from BMCM ΔOPN.   Only kinases and proteins with 
significantly different phosphorylation or expression between at least two treatments are 
shown.  
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Table 2: Malignancy-associated kinases and protein of interest identified by the 
Human Phospho-Kinase Array in response to bone-derived OPN 
Protein	  
Name 
Phosphorylation	  
Site 
Function/Involvement	  in	  Malignancy References 
WNK-1 T60 
• Serine/threonine protein kinase 
• Participates in cell proliferation and 
migration 
• Involved in differentiation of neural 
progenitor cells 
 
[104] 
PRAS40 T246 
• Acts at the intersection of the Akt 
and mammalian-target of rapamycin 
(mTOR)-mediated signaling 
pathways 
• Acts downstream of OPN to 
influence cell migration 
 
[83,	  105] 
HSP60 - 
• Increased levels of HSP60 observed 
in multiple different cancers, plays 
an essential role in malignant cell 
survival 
• Interaction between HSP60 and β-
catenin promotes metastasis 
[106] 
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6 DISCUSSION 
 
One in nine Canadian females are expected to develop breast cancer in their 
lifetime and one in 32 of all Canadian females are expected to die of breast cancer [7]. 
About 85% of all breast cancer patients that die from their disease are expected to harbor 
bone metastases [107]. Bone metastases pose an extreme burden for breast cancer 
patients, resulting in pain, fractures and hypercalcaemia. The current clinical course of 
management lacks treatments that cure, reduce or prevent malignant skeletal lesions 
[107].  
Elucidation of the steps involved in the metastatic cascade is vital for the 
development of therapeutics that can increase progression-free and overall survival of 
breast cancer patients. So far, scientific research efforts have shown that the process of 
metastasis is highly inefficient and that subsets of malignant cells with a stem-like 
phenotype are most likely to form metastases in a secondary site [13, 23, 34, 39]. 
Moreover, breast cancer repeatedly metastasizes to specific organs in the human body. 
This observed organ tropism implies a role for the microenvironment in the establishment 
and progression of metastases in distant organs [12, 37].  
Bone is the most common site of secondary growth in metastatic breast cancer 
patients, suggesting an environment particularly conducive to the development of 
metastases [60].  It is now clear that both soluble and insoluble factors within the bone 
microenvironment contribute to the progression of malignant disease. This thesis focuses 
on the soluble factors within the bone microenvironment that promote the formation of 
breast cancer lesions in the bone. We used an ex vivo representation of the bone 
microenvironment to study soluble factors in bone and hypothesized that one specific 
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soluble factor, OPN, promotes the migration and stem-like behaviour of breast cancer 
cells in BMCM and that the interaction of bone-derived OPN with breast cancer cells 
activates downstream intracellular signaling responses.   
6.1 Summary of Experimental Findings 
1. Bone marrow-conditioned media (BMCM) contains multiple soluble factors that 
could assist in the establishment of breast cancer metastases in bone, such as 
osteopontin (OPN), basic fibroblast growth factor (bFGF), intracellular adhesion 
molecule-1 (ICAM-1), insulin-like growth factor-2 (IGF-2) and matrix-
metalloproteinase-14 (MMP-14).  
2. Bone-derived OPN promotes the tumorsphere and colony-forming abilities in 
MDA-MB-231 breast cancer cells.  
3.  Bone-derived OPN promotes the migration and tumorsphere-forming abilities of 
stem-like ALDHhiCD44+CD24- MDA-MB-231 breast cancer cells to BMCM.  
4. Promotion of MDA-MB-231 and SUM-159 breast cancer cell migration and 
MDA-MB-231 breast cancer cell tumorsphere-forming capacity by bone-derived 
OPN is mediated by the cell surface receptor CD44 and various RGD-dependent 
cell surface cell surface integrins.  
5. Bone-derived OPN causes alterations in migration- and stem cell-related signaling 
pathways in MDA-MB-231 breast cancer cells, including activation of HSP60 and 
phosphorylation of PRAS40 and WNK-1.  
6.2 Implications of Experimental Findings 
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This study supports the hypothesis that bone-derived OPN promotes the migration 
and stem-like behaviour of breast cancer cells via CD44 and RGD-dependent cell surface 
integrins and affects the phosphorylation and activation of downstream signaling 
pathways in breast cancer cells (Figure 14). There exists in the literature a wide breadth 
of knowledge on the effect of tumor-derived OPN in multiple steps of the metastatic 
cascade, however much less research has been conducted on the effect of host-derived 
OPN in the tumor microenvironment.  
It is thought that host-derived OPN differs from tumor-derived OPN both 
structurally and functionally. Current literature suggests that tumor-derived OPN is less 
phosphorylated than host-derived OPN [83]. One study showed that transformation of 
normal rat kidney cells changes OPN from highly phosphorylated to less phosphorylated 
and OPN produced by Ras-transformed fibroblasts is less phosphorylated than OPN 
produced by osteoblasts [108]. Kazanecki et al (2007) proposed that the differing 
phosphorylation profiles of host-derived and tumor-derived OPN affects its function and 
that the less phosphorylated, tumor-derived OPN is more effective at promoting cancer 
progression by protecting cells from the immune response, inhibiting apoptosis and 
increasing anchorage independence and metastasis while host-derived OPN serves as a 
chemoattractant for multiple cells of the immune system, such as macrophages, that 
inhibit tumor growth when recruited to the lesion site [109, 110]. It is also suggested that 
tumor-derived OPN better supports invasiveness while host-derived OPN promotes 
adhesion to components of the extracellular matrix such as fibronectin and vitronectin. 
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Figure 14 Summary of Experimental Findings 
Bone-derived osteopontin promotes the migration of breast cancer cells toward bone as 
well as the stem-like behavior of breast cancer cells in bone by interacting with cells via 
the CD44 cell surface receptor and the RGD-dependent cell surface integrins. 
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Our work helps elucidate the contribution of host-derived OPN – specifically bone-
derived OPN – to the metastatic progression of breast cancer within the bone. 
6.2.1 Bone-Derived OPN Promotes the Migration of Breast Cancer Cells 
 
Firstly, we showed that host-derived OPN, specifically soluble bone-derived 
OPN, can in fact contribute to the metastatic potential of breast cancer cells by increasing 
their migration towards bone-conditioned media. This finding is supported by the work of 
others; Nemoto et al (2001) found that OPN-deficient mice displayed less colonization 
and growth of injected melanoma cells to bone than wild-type mice [89]. Chakraborty et 
al  (2008) showed similar results, demonstrating that OPN-null mice have a slower 
growth rate of tumors compared to wild type mice [89, 111]. These studies, taken 
together with our results, suggest that OPN increases breast cancer cell migration to and 
colonization in bone, thus promoting breast cancer bone metastases.  
Both the MDA-MB-231 and SUM-159 breast cancer cells displayed reduced 
migration towards BMCM depleted of OPN compared to non-depleted BMCM. 
However, levels of migration toward BMCM depleted of OPN were still significantly 
higher than migration toward basal media, suggesting that other factors within the 
BMCM may be contributing to the migration of breast cancer cells. The RayBio® Biotin 
label-based mouse antibody array identified multiple soluble factors that could be 
contributing to this observed migratory effect. One such protein is matrix 
metalloproteinase-14 (MMP-14; MTI-MMP). MMP-14 can be membrane bound or found 
in the soluble form; the type 1 transmembrane MMP is expressed by both stromal cells 
and breast cancer cells and undergoes shedding to produce multiple soluble active and 
inactive fragments [112]. Multiple different types of MMPs are known to contribute to 
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carcinogenesis through extracellular matrix remodeling and cancer cell migration. 
Elevated levels of soluble MMP-14 specifically have been detected in the plasma of 
breast cancer patients and it is known to be a critical protein in cancer progression as it is 
responsible for invasion through collagen networks and collagenolysis [113]. Tobar et al  
(2014) showed that MMP-14 produced by bone marrow stromal cells sheds epithelial 
endoglin, a membrane bound glycoprotein that has tumor suppressor effects by 
attenuating the expression of TGF-β1. By silencing endoglin, MMP-14 enhances the 
migratory properties of human breast cancer cells [101].  Zarrabi et al (2011) have shown 
that MMP-14 can crosstalk with CD44, activating major players in migratory signaling 
pathways downstream of CD44 such as MAPK and PI3K [114].   
Intercellular adhesion molecule (ICAM)-1 is also of interest when considering 
breast cancer migration toward BMCM. ICAM-1 is expressed on the surface of 
endothelial cells, leukocytes and cancer cells and can also be shed into the circulation in 
soluble form. It is an immunoglobulin involved in facilitating adhesion of immune cells 
to endothelia in the healthy human body [115]. However, extensive research shows that 
ICAM-1 also plays a role in malignancy. Elevated levels of soluble ICAM-1 are present 
in breast cancer patients and recently, Schröder et al (2011) showed that ICAM-1 
expression is significantly associated with poor prognosis in breast cancer patients, 
specifically a poorly differentiated phenotype, negative ER status and positive lymph 
node involvement [116]. Binding of soluble ICAM-1 to target cells has been shown to 
modulate migration and angiogenesis via the activation of signaling cascades involving 
MAPK and Src, thus it is possible that ICAM-1 plays a role in the migration of breast 
cancer cells to BMCM [117].  
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6.2.2 Bone-Derived OPN Promotes the Stem-Like Phenotype of Breast 
Cancer Cells in Bone 
In this study, we also assessed the ability of bone-derived OPN to influence the 
stem-like behaviours of limiting dilution tumorsphere-forming ability and colony-
forming ability of breast cancer cells in BMCM. To assess these properties, we used the 
sphere-limiting dilution assay (SLDA) and the colony-forming assay. The SLDA uses a 
limiting-dilution analysis to quantify the number of tumorsphere initiating cells present in 
populations grown in nonadherent conditions [118] and the colony-forming assay 
measures the ability of cells to differentiate and proliferate into colonies at very low 
numbers. To our knowledge, our study is the first to show that bone-derived OPN 
promotes the tumorsphere-forming capacity and colony-forming ability of breast cancer 
cells.  
In normal tissues, stem cells reside in a specialized niche that influences their 
stem-like properties and differentiation fates via cell-to-cell interactions, various secreted 
soluble factors and extracellular matrix components [59, 119]. This niche helps maintain 
homeostasis, influencing a stem cell’s ability remain quiescent, self-renew, or 
differentiate; thus carefully regulating the size and activity of the stem cell pool [59, 119].  
The bone marrow is known to provide an optimal niche for the maintenance of 
hematopoietic stem cells (HSCs). HSCs migrate toward and reside within the endosteal 
region of bone that lies between the bone and bone marrow interface [59]. It has been 
shown that contact between osteoblasts and HSCs at the endosteal surface and within 
trabecular bone is particularly important in modulating HSC proliferation and 
hematopoiesis [59, 120]. It has recently become clear that OPN is integral in mediating 
the effects of osteoblasts on HSCs within healthy bone. Nilsson et al (2005) have shown 
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that osteoblast-secreted OPN promotes migration and lodging of HSCs within the 
endosteal region; when transplanting HSCs into a normal hematopoietic environment, 
they settle almost exclusively into the endosteal region of the bone, however when 
transplanting HSCs into an OPN-/- environment, there is a random distribution of the cells 
throughout the bone marrow [121]. Studies by this group also suggest that OPN 
maintains hematopoietic progenitor cell (HPCs) quiescence within the bone marrow 
[121].  HPCs were isolated from wild type and OPN-/- mice fed bromodeoxyuridine 
(BrdU) continuously for four weeks; HPCs harvested from wild type animals did not 
show any incorporation of BrdU, suggesting that HPCs were maintained in the quiescent 
state, whereas almost all HPCs isolated from OPN-/- mice displayed incorporation of 
BrdU [121].  
Similar to healthy stem cells within the normal bone marrow niche, stem-like 
cancer cells are also influenced and maintained by the microenvironment in which they 
reside. Stromal cells play a major role in maintaining a microenvironment suitable for 
cancer stem cells; these cell types include osteoblasts, osteoclasts, cancer-associated 
fibroblasts (CAFs), infiltrating leukocytes, mesenchymal stem cells (MSCs), and tumor 
associated macrophages (TAMs) which interact with CSCs via direct contact or by 
secreting various growth factors and cytokines [122].   
Recent work has implicated OPN in the maintenance of “stemness” in different 
types of cancers. Pietras et al (2014) showed that OPN was able to promote stemness in 
proneural glioblastoma [123]. This study used two functional assays to measure 
stemness; (1) the drug efflux-based side population (SP) assay, which was previously 
described to enrich for stem-like tumor initiating cells in human and murine glioma by 
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their ability to exclude Hoechst dye via ABC transporter activity [124] and (2) the 
colony-forming assay following irradiation, as well as the expression of a panel of stem-
cell markers, including Nanog, Sox2, Oct4 and Id1. This study found that OPN had the 
ability to increase the amount of cells displaying the SP phenotype within glioma primary 
cultures, suggesting that OPN was necessary to induce the stem-like phenotype. They 
also found that glioma primary cultures treated with OPN displayed up-regulated Nanog, 
Sox2, Oct4 and Id1 stem cell markers. Finally, glioma primary cultures treated with OPN 
formed more colonies in a colony-forming assay following irradiation relative to control 
cells.  
Cao et al (2015) showed that OPN promotes a cancer stem cell-like phenotype in 
hepatocellular carcinoma cells. They found that OPN expression is correlated with 
hepatocellular carcinoma (HCC) SP fractions that display high self-renewal and 
tumorigenic properties and was highly expressed in dormant cells, spheroids and chemo-
resistant cancer cells [125]. They also found that HCC cells exhibited a dramatically 
decreased ability to form colonies and spheroids in colony-forming assays and 
tumorsphere-forming assays when OPN is knocked down with an shRNA construct in 
HCC cells [125]. These cells also displayed a reduction in stemness-related genes, 
including HIF-1α, OCT4, Nanog, CK19, BMI-1 and Notch1 and decreased tumorgenicity 
in immunodeficient mice [125].  
The aforementioned studies by Pietras et al (2014) and Cao et al (2015) focused 
on OPN derived from carcinoma cells however, given the role of the microenvironment 
in maintaining CSC phenotype and activity and our data showing that bone-derived OPN 
promotes the tumorsphere and colony-forming capabilities of breast cancer cells in vitro, 
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it is possible that OPN within the bone microenvironment also plays a crucial role in 
metastatic tumor progression by maintaining the stemness of breast cancer cells that have 
metastasized to bone. Our work proposes a novel function for bone-derived OPN in the 
maintenance of breast cancer cell “stemness” and thus suggests a role for bone-derived 
OPN in the establishment and maintenance of heterogeneous breast cancer tumors in 
bone.  
6.2.3 The Role of CD44 and RGD-Dependent Cell Surface Integrins in 
the Bone-Derived OPN Mediated Migration and Stem-Like 
Behavior of Breast Cancer Cells 
Given the observed functional role of bone-derived OPN in promoting the 
migration and stem-like behaviour of breast cancer cells, we next explored the 
mechanism by which bone-derived OPN influences these functions of breast cancer cells. 
Our results demonstrate that bone-derived OPN influences the migration and 
tumorsphere-forming ability of breast cancer cells via the cell surface receptor CD44 and 
RGD-dependent cell surface integrins.  
CD44 is encoded by 20 exons, 7 of which make the extracellular domain of the 
standard form of CD44 (CD44s). Variants of CD44 arise through the alternative splicing 
of at least 12 of the 20 exons [126]. Cell surface expression of CD44 on macrophages and 
osteoclasts has been shown to effect normal cell motility through interaction with OPN 
[127, 128]. Receptor-ligand interactions between CD44 and OPN have also been 
implicated in malignancy, specifically related to migration as well as other steps in the 
metastatic cascade. Weber et al first showed in 1996 that OPN interacts with CD44 and 
then went on to show that the interaction between CD44 and cancer cell-secreted OPN 
promotes the migration of tumor cells to specific sites of metastasis formation [129, 130]. 
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Katagiri et al (1999) later showed that OPN is able to bind to several CD44 variants in an 
RGD-dependent and independent manner on both the N-terminal and C-terminal 
fragments of OPN to promote cell spreading, motility and chemotactic behavior [131]. 
Khan et al (2005) then showed that incubating T1NT tumorigenic human breast cancer 
cells with monoclonal antibodies recognizing all isoforms of CD44 or the specific 
variants of CD44 v6 or v9 resulted in a significant decrease in OPN-mediated cell 
migration and that OPN enhances CD44 expression at both the mRNA and protein level 
and increases the localization of CD44 to the cell membrane surface [132]. Our lab also 
recently showed that breast cancer cells preferentially migrate toward lung-derived OPN 
in a CD44-dependent manner [92].  
The CD44-OPN interaction is also thought to facilitate OPN’s effect on cancer 
cell stemness. The ability of OPN to maintain glioma stemness phenotypes in the 
perivascular niche is shown to occur in a CD44-dependent manner; mouse models of 
glioma that were CD44-/- or CD44+/- showed better survival compared to controls, an 
effect shown to be mediated through downstream enhancement of HIF-2α activity [123]. 
The current study adds to this breadth of knowledge, showing that bone-derived OPN 
influences breast cancer cell migration and the tumorsphere-forming ability of breast 
cancer cells via CD44. 
The RGD-dependent cell surface integrins include α5β1, α8β1 and all αv-
containing integrins. These integrins recognize ligands that contain the RGD motif (Arg-
Gly-Asp), mainly found in components of the extracellular matrix such as OPN, 
fibronectin, vitronectin and nephronectin [133]. The interaction between OPN and these 
cell surface integrins is used in multiple different settings in the healthy body, including 
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facilitating the migration and adhesion of cell types such as osteoclasts, multiple different 
types of epithelial cells and smooth muscle cells via clustering and functional activation 
of the focal adhesion kinase complex [134]. Cell surface integrins also prove particularly 
important in malignancy, as increased expression of these integrins on tumor cells 
enhances their tumorigenic properties, specifically migration and adhesion. OPN-
mediated migration in breast cancer has been shown to involve many of these integrins, 
including αvβ1, αvβ5 [135, 136] and α8β1 [137]. The cell surface integrin that seems to 
be most commonly associated with OPN’s effect in malignancy is the αvβ3 heterodimer. 
Increased expression of αvβ3 during breast cancer tumorigenesis and progression makes 
tumor cells more responsive to OPN and thus enhances tumorigenic properties such as 
migration and adhesion [86].  Interestingly, it has been shown that breast cancer cell lines 
can express variable amounts of different cell surface integrins and thus depend on 
certain integrins over others in their migratory and adhesive functions. Wong et al  (1998) 
showed that the highly metastatic MDA-MB-435 breast cancer cell line expresses high 
levels of αvβ3 while the non-metastatic MCF-7 breast cancer cell line expressed 
significantly lower levels of αvβ3 [138]. Similarly, van der Pluijm et al (1997) found 
higher levels of expression of α2β1, α3β1, α5β1 and αvβ3 in the highly metastatic MDA-
MB-231 breast cancer cell line compared to the less malignant MCF-7, T47D and ZR75-
1 breast cancer cell lines [139] and found that use of the GRGDS peptide blocked the 
adhesion of MDA-MB-231 to bone matrix molecules. Tuck et al (2000) then showed that 
the highly metastatic MDA-MB-435 breast cancer cell line depends more on the αvβ3 
heterodimer for OPN-mediated migration than αvβ5 or β1 integrins, whereas the non-
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metastatic breast cancer cell lines, 21PT and 21NT, migrated in an αvβ5 or β1-dependent 
and an αvβ3-independent manner [140].   
In keeping with these studies, our results show cell line-specific migratory 
responses when the OPN-CD44 or the OPN-RGD-dependent cell surface integrin 
interactions are abrogated. The MDA-MB-231 cells display significantly decreased 
migration to BMCM depleted and non-depleted of OPN when the RGD motif is blocked 
compared to when the CD44 cell surface receptor is blocked. In contract, the SUM-159 
cells display the opposite effect; they show significantly reduced migration when the 
CD44 cell surface receptor is blocked compared to when the RGD motif is blocked. Flow 
cytometry analysis revealed that both cell lines express significant amounts of CD44 and 
similarly moderate amounts of RGD-dependent β1, αvβ3 and αvβ5 and RGD-
independent α9β1, suggesting that the differences in migratory function observed could 
be dependent on the expression of other cell surface integrins on the MDA-MB-231 such 
as α5β1 and α8β1.  
We also showed that blocking RGD-dependent cell surface integrins on MDA-
MB-231 cells attenuates their tumorsphere-forming capacity. These results are supported 
by those of Cao et al (2015), who showed that OPN promotes the stem cell-like 
phenotype of HCC cells via the αvβ3 cell surface integrin, which in turn activates the 
downstream transcription factor NF-κB and hypoxia-related protein HIF-1α [125].  
6.2.4 Bone-Derived OPN Causes Phosphorylation and Expression 
Changes in Migratory and Stem Cell-Related Pathways in Breast 
Cancer Cells 
OPN influences a number of signaling pathways via communication with CD44 
and RGD-dependent cell surface integrins to mediate steps of metastatic cascade, 
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including migration, cell proliferation and survival, adhesion and angiogenesis. Soluble 
OPN can promote the migration, proliferation and survival of tumor cells via αvβ1, αvβ3, 
αvβ5 and CD44 while adhesion and angiogenesis are promoted via αvβ3 [83]. The 
interaction of OPN with αvβ1 and αvβ5 typically result in the upregulation of paxillin, 
Crk and Ras while signaling via αvβ3 activates Src and the focal adhesion kinase 
complexes and their downstream effectors such as Erk1/2, uPA, NF- κB, OPG and the 
FAK and PI3K/Akt axis [83]. Interaction of OPN with CD44 activates the CD44-ERM 
complex, as well as promoting the phosphorylation of Akt and the activation of MAPK 
[83]. The migratory response of cells to OPN also includes the upregulation of epidermal 
growth factor (EGF) and hepatocyte growth factor (HGF) and induces EGF receptor 
(EGFR) receptor expression and tyrosine kinase activity as well as an increase in the 
kinase activity of the HGF receptor Met [140, 141].  
 Given the effect of OPN on multiple downstream signaling pathways within 
tumor cells, we wanted to explore the effect that bone-derived OPN has on the 
phosphorylation of common kinases and the activation of 2 related proteins in MDA-MB-
231 human breast cancer cells using the Human Phospho-Kinase Array (R&D Systems). 
This array contained proteins that are commonly activated and phosphorylated in 
response to soluble OPN, including Akt, EGFR, Erk1/2 and FAK. With use of this array, 
we identified three novel factors that appear to be influenced by bone-derived OPN. Our 
results indicate that the presence of bone-derived OPN causes significant increases in the 
phosphorylation of PRAS40 and Wnk-1 and an upregulation in the expression of HSP60. 
We have yet to validate the results of the array with immunoblotting, however these three 
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proteins are interesting candidates for the downstream signaling that may be activated in 
breast cancer cells in response to bone-derived OPN.  
6.2.4.1 PRAS40 
PRAS40 is a proline-rich substrate of Akt and mTORC1. It acts at the intersection 
of the Akt and mammalian target of rapamycin (mTOR) signaling pathways and has been 
used in studies as a marker for PI3K pathway activation. The PI3K-Akt signaling 
pathway regulates many normal cellular processes including cell motility, proliferation, 
cell growth and cell survival. It has been extensively studied in relation to carcinogenesis 
and the aberrant expression of many components within this pathway has been implicated 
in numerous human cancers [142]. Andersen et al (2010) found that expression of 
phospho-PRAS40 was up-regulated in 40% of primary breast cancer samples and 
correlates with PI3K-Akt signaling and thus predicts Akt inhibitor sensitivity in triple-
negative breast cancer tissues [143]. As previously mentioned, OPN activates the 
PI3K/Akt/mTOR pathway via interaction with αVβ3 to promote migration, invasion and 
cell survival and proliferation thus it is likely that bone-derived OPN may also indirectly 
cause increased phosphorylation of PRAS40 [144].  
6.2.4.2 WNK1 
WNK1 is a seronine-threonine protein kinase that is widely expressed in many 
human tissues. Most research on the WNK protein kinase family has focused on their role 
in the regulation of ion transporters in the kidney and extrarenal tissues, however growing 
evidence suggests that they are involved in various signaling cascades related to human 
cancer. WNK1 is involved in the MAPK cascade and has been shown to be involved in 
EGF-dependent stimulation of ERK1/2 and ERK5 in neural progenitor cells and HeLa 
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cells [104, 145]. Knockdown of WNK1 in these cell types lead to the suppression of 
ERK1/2 by EGF and resulted in greatly reduced cell growth and migration [104]. WNK1 
is also known to phosphorylate Smad2 and negatively affects Smad-mediated gene 
expression, which results in suppression of TGF-β signaling. TGF-β is integral in 
inducing the epithelial-to-mesenchymal transition (EMT) thus loss or inactivation of 
WNK1 activity could promote EMT of epithelial tumor cells [146]. WNK1 is also linked 
to Rho GTPases, which control the dynamics of the cytoskeleton and are integral in cell 
migration and invasiveness [147, 148]. Notably, upregulation of WNK1 in neural tumor 
cells has been correlated with increased invasiveness. WNK1 is also a substrate of Akt, 
suggesting that it may play a role in the PI3K/Akt pathway [145]. Its role in this pathway 
could cause WNK1 to be indirectly phosphorylated by the interaction of bone-derived 
OPN with αvβ3 on breast cancer cells, and thus could contribute to breast cancer 
migration, invasiveness and cell growth downstream of OPN. 
6.2.4.3 HSP60 
Finally, heat shock protein 60 (HSP60) is a chaperone protein that is essential in 
assisting many different newly synthesized proteins fold into their native forms. Research 
focused on HSP60’s role in disease has mostly shown its role in innate immunity and 
cardiac ischemia, however increased HSP60 expression is also observed in a wide variety 
of cancers, including prostate, ovarian, pancreatic and large bowel carcinoma [149]. 
Cellular distribution of HSP60 changes during carcinogenesis; while it is normally found 
in the mitochondria, instead it accumulates in extramitrochondrial sites, such as the 
cytosol, plasma membrane, and secretory vesicles [150, 151]. HSP60 has also been 
shown to accumulate in lymph node-invading tumor cells, possibly suggested a role for 
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HSP60 in metastasis, and to accumulate in tumor cells as a result of treatment with the 
systemic agent 5-azacytidine, conferring tumor cell resistance [149]. Tsai et al (2009) 
recently demonstrated that overexpression of HSP60 induces metastasis in head and neck 
cancer cell lines by interacting with β-catenin and activating its downstream targets, such 
as MMP-14 [106]. Our results from the Human Proteome Profiler array suggest bone-
derived OPN may also have an effect on the expression of HSP60 in breast cancer cells.  
6.3 Limitations to the Study 
This study’s methods rely heavily on the use of an ex vivo model system as a 
surrogate for the bone microenvironment. While this system provided an excellent 
platform in which to study the effect of bone-derived OPN on the migration and stem-like 
behaviour of breast cancer cells, this approach is not without limitations.  
 Firstly, this model only allows the examination of soluble factors within the bone 
marrow microenvironment and excludes insoluble components such as the extracellular 
matrix and the various cell types that are present in bone, including osteoblasts, 
osteoclasts, osteocytes, hematopoietic and mesenchymal stem cells, T cells, erythrocytes 
and platelets. These insoluble factors are known to influence the metastasis of breast 
cancer cells within bone marrow and would be valuable factors to include when 
examining the effect of bone-derived OPN on breast cancer metastasis to bone [3].  
 Secondly, the BMCM is harvested from nude mice and thus consists of murine 
soluble factors. When using this model, it is assumed that these murine soluble factors 
can interact with human breast cancer cells. The mouse genome and human genome are 
highly homologous; of the 4,000 genes that have been studied, less than ten exist in one 
species but not in the other [152]. Many murine factors are capable of interacting with 
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and stimulating human cells however, it is known that some murine factors are not 
capable of being recognized by human cells and are not compatible with human signaling 
pathways [153]. Thus, this model may not be ideal for studying the effect of all soluble 
factors within the BMCM on breast cancer cell malignant cell behavior. Additionally, the 
use of nude mice excludes a significant proportion of the immune system contribution to 
breast cancer cell metastasis in the bone. The immune system is particularly important 
when studying the effects of OPN on breast cancer cells, as OPN is known to recruit 
macrophages that can inhibit tumor growth at the site of metastasis [83]. However, the 
use of the nude murine platform is beneficial in that the results obtained can be closely 
related to previous and future in vivo studies in the same mouse strain.  
 Finally, the results of this study rely on the use of immortalized breast cancer cell 
lines as opposed to primary human breast cancer cells. Although our cells are routinely 
authenticated, cell lines have the ability to mutate in vitro as a result of being maintained 
outside of their native environment (tissue plastic vs. the extracellular matrix) and due to 
their inherent lack of fully functioning DNA repair mechanisms. Therefore although 
immortalized cell lines are well-characterized, commercially available, and easy to grow 
in culture, they still may not accurately represent the true behavior that might be seen if 
primary patient-derived breast cancer cells were used.   
6.4 Future Directions 
While this study contributes to the breadth of knowledge implicating OPN in the 
metastasis of breast cancer to bone, some unanswered questions remain that should be 
addressed to help form a more complete picture of breast tumorigenesis in the bone 
microenvironment.  
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Firstly, rescue experiments should be performed with respect to OPN’s effect on 
the tumorsphere-forming and colony-forming capacity of breast cancer cells in BMCM. 
OPN should be added to BMCM that has been depleted of OPN and used in the SLDA 
and colony-forming assay to show that OPN is solely responsible for the reduction in the 
tumorsphere- and colony-forming capabilities of breast cancer cells in BMCM.  
 Secondly, it would be beneficial to show the localization of OPN in the bone and 
its cell surface receptors and integrins on in vivo breast cancer bone metastases to support 
the conclusion that bone-derived OPN is interacting with CD44 and RGD-dependent cell 
surface integrins to facilitate the metastatic process.  
Additionally, in order to appropriately conclude that bone-derived OPN results in 
the phosphorylation of PRAS40 and WNK1 and the upregulation of HSP60, 
immunoblotting needs be performed with cell lysates exposed to basal media, BMCM 
and BMCM depleted of OPN. Immunoblotting would support the findings of the Human 
Proteome Profiler array, as the array’s results alone are not robust enough to draw 
definite conclusions. It would also be interesting to repeat the array with other breast 
cancer cell lines (i.e. SUM-159) to identify any differences in cellular signaling in 
response to bone-derived OPN. As shown in the results of this study, MDA-MB-231 and 
SUM-159 cells both respond to the presence of bone-derived OPN but their response 
seems to depend more heavily on one cell surface receptor/integrin over another in a cell 
line-specific manner. It is possible that the different cell lines have differing cell signaling 
responses to OPN as well.  
It would also be beneficial to our conclusions to show the effect of bone-derived 
OPN on breast cancer metastases in vivo. Some studies have used OPN knockout mice to 
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explore the metastatic behavior of breast cancer in relation to OPN, however these 
models have all excluded the effect on the immune system as they have used nude mice. 
Repeating these studies in an OPN knockout mice strain using a syngeneic injection 
model would be interesting, as it has been hypothesized that the recruitment of 
macrophages to the tumor site by OPN can slow tumor growth and thus may also play a 
role in initially inhibiting the development of bone metastases [66, 154].  
Finally, it is clear that other soluble factors within the BMCM can influence 
breast cancer cell migration to bone; although migration was significantly reduced in 
response to BMCM depleted of OPN compared to non-depleted BMCM, migratory levels 
were still higher than migration toward basal media. Other factors to explore include 
MMP-14 and ICAM-1.  
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7 CONCLUSIONS 
 
This thesis investigated the role of bone-derived OPN in the metastatic behavior 
of breast cancer cells and their penchant for bone as a secondary growth site. Our work 
has shown that bone-derived OPN is integral to the metastatic cascade culminating in the 
establishment of skeletal breast cancer metastases. Bone-derived OPN promotes the 
migration of breast cancer cells to bone marrow and thus, assists in attracting breast 
cancer cells to bone. It also contributes to maintaining the stem-like behavior of breast 
cancer cells in bone marrow and thus, may promote the establishment of metastases in 
bone. This thesis also suggests that bone-derived OPN activates a downstream signaling 
response in breast cancer cells involving the phosphorylation of PRAS40 and WNK-1, as 
well as the activation of HSP60.  
Broadly, this thesis focused on the contribution of the bone microenvironment to 
metastatic breast cancer. While the cancer research community has known about specific 
metastatic patterns and organ preferences that breast cancers exhibit for over a century, 
only recently have efforts focused on the role of the secondary site or “soil” in promoting 
and supporting metastatic growth at these sites. It is becoming increasingly clear that the 
microenvironment, specifically the bone, offers an optimal niche for the establishment 
and progression of metastases; our study shows that bone-derived soluble factors – 
specifically OPN – contribute to this process, possibly by interacting with stem-like 
breast cancer cells. This knowledge is valuable to our efforts in attempting to treat 
metastatic disease in breast cancer patients, as targeting the OPN-breast cancer stem cell 
interaction in addition to using chemotherapies and radiotherapies could help mitigate 
breast cancer bone metastases.  
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Number Name Number Name Number Name Number Name
1 P-1a 61 CCL8 / MCP-2 121 Fas Ligand 181 Blank
2 P-2a 62 CCR10 122 FCrRIIB / CD32b 182 Blank
3 P-3a 63 CCR3 123 FGF R3 183 Blank
4 Blank 64 CCR4 124 FGF R4 184 Blank
5 Blank 65 CCR6 125 FGF R5 beta 185 Blank
6 NEG 66 CCR7 126 FGF-21 186 Blank
7 NEG 67 CCR9 127 Fit-3 Ligand 187 Blank
8 Blank 68 CD11b 128 FLRG (Follistatin) 188 Blank
9 6Ckine 69 CD14 129 Follistatin-like 1 189 IL-1 R9
10 Activin A 70 CD195 130 Fractalkine 190 IL-1 RI
11 Activin C 71 CD27 / TNFRSF7 131 Frizzled-1 191 IL-1 RII
12 Activin RIB / ALK-4 72 CD27 Ligand / TNFSF7 132 Frizzled-6 192 IL-2
13 Adiponectin / Acrp30 73 CD30 L 133 Frizzled-7 193 IL-2 R alpha
14 Blank 74 Blank 134 Blank 194 Blank
15 Blank 75 Blank 135 Blank 195 Blank
16 Blank 76 CD30 136 Galectin-3 196 Blank
17 Blank 77 CD40 137 G-CSF 197 Blank
18 Blank 78 CD40 Ligand / TNFSF5 138 GDF-1 198 Blank
19 Blank 79 Cerberus 1 139 GDF-3 199 Blank
20 Blank 80 Chordin-Like 2 140 GDF-5 200 Blank
21 NEG 81 Coagulation Factor III / Tissue Factor 141 GDF-8 201 Blank
22 NEG 82 Common gamma Chain / IL-2 R gamma 142 GDF-9 202 Blank
23 Blank 83 CRG-2 143 GFR alpha-2 / GDNF R alpha-2 203 Blank
24 AgRP 84 Cripto 144 GFR alpha-3 / GDNF R alpha-3 204 IL-2 R beta
25 ALCAM 85 Crossveinless-2 145 GFR alpha-4 / GDNF R alpha-4 205 IL-3
26 Angiopoietin-like 2 86 Cryptic 146 GITR 206 IL-3 R alpha
27 Angiopoietin-like 3 87 Csk 147 GITR Ligand / TNFSF18 207 IL-3 R beta
28 AR (Amphiregulin) 88 CTACK 148 Glut2 208 IL-4
29 Artemin 89 CTLA-4 / CD152 149 GM-CSF 209 IL-4 R
30 Axl 90 CXCL14 / BRAK 150 Granzyme B 210 IL-5
31 Blank 91 CXCL16 151 Granzyme D 211 Blank
32 Blank 92 CXCR2 / IL-8 RB 152 Granzyme G 212 Blank
33 Blank 93 CXCR3 153 Gremlin 213 Blank
34 Blank 94 CXCR4 154 Growth Hormone R 214 Blank
35 Blank 95 CXCR6 155 HGF R 215 Blank
36 Blank 96 DAN 156 HGF 216 NEG
37 Blank 97 Decorin 157 HVEM / TNFRSF14 217 NEG
38 Blank 98 DKK-1 158 ICAM-1 218 Blank
39 b FGF 99 Dkk-3 159 ICAM-2 / CD102 219 IL-5 R alpha
40 B7-1/CD80 100 Dkk-4 160 ICAM-5 220 IL-6
41 BAFF R / TNFRSF13C 101 DPPIV / CD26 161 ICK 221 IL-6 R
42 BCMA / TNFRSF17 102 DR3 / TNFRSF25 162 IFN-alpha / beta R1 222 IL-7
43 beta-Catenin 103 Dtk 163 IFN-alpha / beta R2 223 IL-7 R alpha
44 Blank 104 Blank 164 Blank 224 Blank
45 Blank 105 Blank 165 Blank 225 Blank
46 Blank 106 EDAR 166 IFN-beta 226 Blank
47 Blank 107 EGF R 167 IFN-gamma 227 Blank
48 Blank 108 EG-VEGF / PK1 168 IFN-gamma R1 228 Blank
49 Blank 109 Endocan 169 IGFBP-1 229 Blank
50 Blank 110 Endoglin / CD105 170 IGFBP-2 230 Blank
51 Blank 111 Endostatin 171 IGFBP-3 231 NEG
52 Blank 112 Eotaxin 172 IGFBP-5 232 NEG
53 Blank 113 Eotaxin-2 173 IGFBP-6 233 Blank
54 BLC 114 Epigen 174 IGFBP-rp1 / IGFBP-7 234 IL-9
55 BTC (Betacellulin) 115 Epiregulin 175 IGF-I 235 IL-9 R
56 Cardiotrophin-1 116 Erythropoietin (EPO) 176 IGF-II 236 IL-10
57 CCL1 / I-309 / TCA-3 117 E-Selectin 177 IL-1 alpha 237 IL-10 R alpha
58 CCL28 118 FADD 178 IL-1 beta 238 IL-11
59 CCL4 / MIP-1 beta 119 FAM3B 179 IL-1 R4 / ST2 239 IL-12 p40/p70
60 CCL7 / MCP-3 / MARC 120 Fas / TNFRSF6 180 IL-1 R6 / IL-1 R rp2 240 IL-12 p70  
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Number Name Number Name Number Name Number Name
241 Blank 301 LIX 361 Spinesin Ectodomain 421 Blank
242 Blank 302 LRP-6 362 TACI / TNFRSF13B 422 Blank
243 Blank 303 L-Selectin 363 TARC 423 Blank
244 Blank 304 Lungkine 364 TCA-3 424 Blank
245 Blank 305 Lymphotactin 365 TCCR / WSX-1 425 Blank
246 Blank 306 Lymphotoxin beta R / TNFRSF3 366 TECK 426 NEG
247 Blank 307 MAdCAM-1 367 TFPI 427 NEG
248 Blank 308 MCP-1 368 TGF-beta 1 428 Blank
249 IL-12 R beta 1 309 MCP-5 369 TGF-beta 2 429 Urokinase
250 IL-13 310 M-CSF 370 TGF-beta 3 430 VCAM-1
251 IL-13 R alpha 2 311 MDC 371 TGF-beta RI / ALK-5 431 VE-Cadherin 
252 IL-15 312 MFG-E8 372 TGF-beta RII 432 VEGF
253 IL-15 R alpha 313 MFRP 373 Thrombospondin 433 VEGF R1
254 Blank 314 Blank 374 Blank 434 Blank
255 Blank 315 Blank 375 Blank 435 Blank
256 Blank 316 MIG 376 Thymus Chemokine-1 436 VEGF R2
257 Blank 317 MIP-1 alpha 377 Tie-2 437 VEGF R3
258 Blank 318 MIP-1 gamma 378 TIMP-1 438 VEGF-B
259 Blank 319 MIP-2 379 TIMP-2 439 VEGFC
260 Blank 320 MIP-3 alpha 380 TIMP-4 440 VEGF-D
261 Blank 321 MIP-3 beta 381 TL1A / TNFSF15 441 WIF-1
262 Blank 322 MMP-2 382 TLR1 442 WISP-1 / CCN4
263 Blank 323 MMP-3 383 TLR2 443 Blank
264 IL-16 324 MMP-9 384 TLR3 444 NEG
265 IL-17 325 MMP-12 385 TLR4 445 NEG
266 IL-17BR 326 MMP-14 / LEM-2 386 TMEFF1 / Tomoregulin-1 446 Blank
267 IL-17C 327 MMP-24 / MT5-MMP 387 TNF RI / TNFRSF1A 447 Blank
268 IL-17D 328 Neuregulin-3 / NRG3 388 TNF RII 448 P-3b
269 IL-17E 329 Neurturin 389 TNF-alpha 449 P-2b
270 IL-17F 330 NGF R / TNFRSF16 390 TNF-beta / TNFSF1B 450 P-1b
271 IL-17R 331 NOV / CCN3 391 Blank
272 IL-17RC 332 Osteoactivin / GPNMB 392 Blank
273 IL-17RD 333 Osteopontin 393 Blank
274 IL-18 R alpha/IL-1 R5 334 Osteoporotegerin 394 Blank
275 IL-20 335 OX40 Ligand / TNFSF4 395 Blank
276 IL-20 R alpha 336 PDGF C 396 Blank
277 IL-21 337 PDGF R alpha 397 Blank
278 IL-21 R 338 PDGF R beta 398 Blank
279 IL-22 339 Pentraxin3 / TSG-14 399 TPO
280 IL-22BP 340 PF-4 400 TRAIL / TNFSF10
281 IL-23 341 PlGF-2 401 TRAIL R2 / TNFRSF10B
282 IL-23 R 342 Progranulin 402 TRANCE / TNFSF11
283 IL-24 343 Prolactin 403 TREM-1
284 Blank 344 Blank 404 Blank
285 Blank 345 Blank 405 Blank
286 IL-27 346 P-Selectin 406 TROY
287 IL-28 / IFN-lambda 347 RAGE 407 TSLP
288 IL-31 348 RANTES 408 TSLP R
289 IL-31 RA 349 RELM beta 409 TWEAK / TNFSF12
290 Insulin 350 Resistin 410 TWEAK R / TNFRSF12
291 Integrin beta 2 / CD18 351 S100A10 411 Ubiqultin
292 I-TAC 352 SCF 412 uPAR
293 KC 353 SCF R / c-kit 413 Blank
294 Kremen-1 354 SDF-1 414 Blank
295 Kremen-2 355 Serum Amyloid A1 415 Blank
296 Lefty-1 356 Shh-N 416 Blank
297 Leptin R 357 SIGIRR 417 Blank
298 LEPTIN(OB) 358 SLPI 418 Blank
299 LIF 359 Soggy-1 419 Blank
300 LIGHT / TNFSF14 360 SPARC 420 Blank  
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Appendix C: R&D Human Phospho-Kinase Array Target List 
• Akt (S473)  
• Akt (T308) 
• AMPK alpha1 (T174) 
• AMPK alpha2 (T172) 
• beta-Catenin 
• Chk-2 (T68) 
• c-Jun (S63) 
• CREB (S133) 
• EGF R (Y1086) 
• eNOS (S1177) 
• ERK1/2 (T202/Y204, 
T185/Y187) 
• FAK (Y397) 
• Fgr (Y412) 
• Fyn (Y420) 
• GSK-3 alpha/beta (S21/S9) 
• Hck (Y411) 
• HSP27 (S78/S82) 
• HSP60 
• JNK pan (T183/Y185, 
T221/Y223) 
• Lck (Y394) 
• Lyn (Y397) 
• MSK1/2 (S376/S360) 
• p27 (T198) 
• p38 alpha (T180/Y182) 
• p53 (S15) 
• p53 (S392) 
• p53 (S46) 
• p70 S6 Kinase (T421/S424) 
• PDGF R beta (Y751) 
• PLC gamma-1 (Y783) 
• PRAS40 (T246) 
• Pyk2 (Y402) 
• RSK1/2/3 (S380/S386/S377) 
• Src (Y419) 
• STAT2 (Y689) 
• STAT3 (S727) 
• STAT3 (Y705) 
• STAT5a (Y694) 
• STAT5a/b (Y694/Y699) 
• STAT5b (Y699) 
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• STAT6 (Y641) 
• TOR (S2448) 
• WNK-1 (T60) 
• Yes (Y426) 
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Curriculum Vitae - Graciella Pio 
 
EDUCATION 
 
Honors BSc 
Western University 
London, ON 
September 2008-June 2013 
• Achieved an Honors Specialization in Biology with a Major in Medical Cell 
Biology 
 
RESEARCH EXPERIENCE 
 
Honors Thesis Project, Allan Lab,  
Department of Anatomy and Cell 
Biology,  
Western University 
London, ON 
September 2012-April 2013 
• Research area: cellular and molecular biology of metastasis 
• Identified two soluble factors that attract whole population breast cancer cells to 
bone marrow 
 
Obstetrics and Gynecology Clinic,  
St. Michael’s Hospital 
Toronto, ON 
May 2011-August 2011 
• Research area: reproductive and infectious diseases, maternal fetal medicine 
• Research roles: managed various ongoing clinical studies, organized information 
sessions for potential study participants, recruited clinic patients as potential study 
participants, organized and analyzed data 
 
Sinclair Lab, Department of Biology,  
Western University 
London, ON 
September 2010-April 2011 
• Research area: animal physiology, biology of arthropods in cold environments 
• Responsible for general laboratory and fly maintenance 
SCHOLARSHIPS and AWARDS 
Scholarships  
• Ontario Graduate Scholarship, (15,000/year) 2014-2015  (accepted) 
• CIHR Strategic Training Program in Cancer Research and Technology Transfer 
Studentship  ($9,050/year), 2013-2015 (accepted) 
• Translational Breast Cancer Unit Studentship from the London Regional Cancer 
Program ($9,050/year), 2014-2015 (accepted) 
• Western Graduate Scholarship ($4500/year), 2013-2015 (accepted) 
Awards  
• CIHR Institute of Cancer Research Travel Award for the Canadian Cancer 
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Research Conference ($1,000) (accepted) 
• Dean’s Honor List (UWO), 2011-2013 
PUBLICATIONS 
 
Pio GM, Piasecnzy M, Xia Y, Goodale D and Allan AL. Bone-derived osteopontin 
mediates the migration and stem-like properties of breast cancer cells. [In preparation for 
International Journal of Cancer]	  
 
ORAL AND POSTER PRESENTATIONS 
 
External Presentations 
• Pio GM, Piaseczny M, Chu JE, Xia Y and Allan AL. The role of bone-derived 
OPN in breast cancer metastasis. Poster presentation, American Association of 
Cancer Research Conference, Philadelphia, PA. April 2015  
• Pio GM, Chu JE, Xia Y and Allan AL. Identification and functional implications 
of bone derived factors in breast cancer migration. Poster presentation, Metastasis 
Research Society Conference, Heidelberg, Germany. June 2014  
• Pio GM, Chu JE, Xia Y and Allan AL. Identification and functional implications 
of bone derived factors in breast cancer migration. Poster presentation, Canadian 
Cancer Research Conference, Toronto, ON. November 2013 
• Pio GM, Chu JE, Xia Y and Allan AL. Identification and functional implications 
of bone derived factors in breast cancer migration. Oral presentation, Ontario 
Biology Day at McMaster University, Hamilton, ON. March 2013 
 
Internal Presentations  
• Pio GM, Piaseczny M, Chu JE, Xia Y and Allan AL. The role of bone-derived 
OPN in breast cancer metastasis. Oral Presentation, London Regional Cancer 
Program Seminar Series. March 2014. 
• Pio GM, Piaseczny M, Chu JE, Xia Y and Allan AL. The role of bone-derived 
OPN in breast cancer metastasis. Poster presentation, London Health Research 
Day. March 2015  
• Pio GM, Piaseczny M, Chu JE, Xia Y and Allan AL. The role of bone-derived 
OPN in breast cancer metastasis. Oral Presentation, Anatomy and Cell Biology 
Research Day. October 2014 
• Pio GM, Chu JE, Xia Y and Allan AL. Identification and functional implications 
of bone derived factors in breast cancer migration. Poster presentation, London 
Health Research Day, London, ON. March 2014  
• Pio GM, Chu JE, Xia Y and Allan AL. Identification and functional implications 
of bone derived factors in breast cancer migration. Oral presentation, London 
Regional Cancer Program Seminar Series. March 2014  
• Pio GM, Chu JE, Xia Y and Allan AL. Identification and functional implications 
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of bone derived factors in breast cancer migration. Poster presentation, Anatomy 
and Cell Biology Day. October 2013 
 
PROFESSIONAL EXPERIENCE 
 
Teaching Assistant,  
Oral Histology, 
Western University 
London, ON 
September 2014-April 2015	  
• Course topic: histology of the oral mucosa and tissue 
Teaching Assistant, Medical Sciences 4900 F/G 
Western University 
London, ON 
September 2013-December 2014 
• Course topic: laboratory techniques with focus on animal models of human disease, real 
time PCR, biochemical assays, histology and medical imaging 
 
Teaching Assistant,  
Translational Models of Cancer 4461b, 
Western University  
London, ON 
January 2014-April 2014 
	  
• Course topic: histology, prognosis, biomarkers, imaging and sites of metastasis of main 
cancer types including historical perspectives of how findings in the basic sciences have 
led to better treatments for cancer 	  	  	  
